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Summary 
Dilated cardiomyopathy (DCM) is a leading cause of heart failure and frequently 
results from postinfectious autoimmunity. Its pathophysiology is modeled by 
experimental autoimmune myocarditis (EAM), a CD4+ T-cell mediated murine 
model of postinfectious heart disease. My thesis focuses on the role of innate 
mechanisms in inflammatory heart disease using the EAM model. In this context 
we specifically addressed the role of the Toll-like Receptor (TLR) signalling 
adaptor molecule MyD88 and the Interferon-alpha-beta Receptor (IFNαβR). 
First, we addressed the role of MyD88 in EAM induction. In contrast to wild-type 
(wt) control littermates, MyD88 deficient mice were protected from EAM after 
immunization with alpha-myosin heavy chain derived peptide (MyHC-alpha) and 
complete Freund`s adjuvant (CFA). Disease resistance of MyD88 deficient mice 
resulted from impaired expansion of heart-specific CD4+ T-cells after 
immunization. We further showed that MyD88 deficient primary antigen 
presenting dendritic cells were defective in their capacity to prime CD4+ T-cells. 
This defect mainly resulted from the inability of MyD88 deficient DCs to release 
TNF-alpha. However, repetitive injection of activated, MyHC- lpha loaded wt 
bone marrow DCs (bmDCs) fully restored T-cell expansion and myocarditis in 
MyD88 deficient mice. We therefore conclude that autoimmune myocarditis 
induction depends on MyD88 signalling of self-antigen presenting cells in the 
peripheral compartments. 
Second, we analyzed the role of MyD88 in the progression of heart failure. After 
wt bmDC immunization, MyD88 deficient and wt mice developed autoimmune 
myocarditis of the same severity and prevalence. Based on this phenotype we 
analyzed the role of MyD88 in the progression of autoimmune myocarditis to 
heart failure. We showed by echocardiographic heart function analysis, that wt 
mice but not MyD88 deficient mice have reduced heart function after initial bmDC 
induced autoimmune myocarditis. We further describe increased fibrosis in wild-
type mice when compared to MyD88 deficient mice when immunized with a novel 
protocol combining bmDC and CFA immunization. We therefore hypothesize that 
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MyD88 mediated IL-1 receptor signalling or the production of MyD88 dependent 
proinflammatory cytokines contribute to the development of post myocardial 
inflammation induced heart failure. In addition, we provide new data to the 
ongoing debate about a heart specific innate stress program that contributes to 
the development of heart failure. 
Third, we analyzed the role of type I interferon receptor signalling in EAM 
induction. MyD88 independent TLR signalling is mainly characterized by the 
induction of a type I interferon (IFN) response. We therefore decided to 
specifically address this alternative pathway of TLR signalling by analyzing EAM 
in IFNαβR deficient mice. We found that IFNαβR deficient mice are protected 
from bmDC induced autoimmune myocarditis. We provide evidence that the 
protection coincides with reduced CD4+ T-cell priming. Further results from 
MyHC-specific wt and IFNαβR T-cell transfer experiments indicate an additional 
role for type I IFN signalling in the recruitment of proinflammatory cells to the 
heart. 
These studies characterize different pathways of TLR signalling and effector 
molecules in the pathogenesis of EAM. Our data clearly demonstrate that MyD88 
and the IFNαβR are essential modulators of the autoimmune process during 
myocarditis induction and heart failure development. 
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Aim of the thesis 
The aim of this thesis was to assess the role of TLR signalling in Experimental 
Autoimmune Myocarditis.  
In preliminary experiments we found that single TLR deficiencies for TLR2, TLR4 
and TLR9 are redundant in the development of EAM. However, it was already 
shown that activation of IL-1 type 1 Receptor (IL-1R) is required for disease 
induction (1). TLRs and The IL-1R belong to the same receptor super-family and 
share intracellular signalling pathways including the Toll-IL-1 Receptor adaptor 
molecule MyD88 (2). Furthermore, MyD88 has been shown to be essential for 
the production of proinflammatory cytokines upon TLR stimulation (3). 
Interestingly, several proinflammatory cytokines, including IL-1, IL-6 and IL-12 
have been described to be essential for EAM induction (2, 4, 5). We therefore 
decided to further address the role of MyD88 in autoimmune myocarditis. This 
was accomplished by examining the susceptibility of MyD88 deficient mice to 
EAM. In determining the function of MyD88 in this disease model, I aimed to 
open insights into the mechanisms involved in EAM induction and the 
development of autoimmunity in general. 
Proinflammatory cytokines have also been associated with the pathogenesis of 
dilated cardiomyopathy and heart failure in general (6-11). However, the 
mechanisms and signals underlying the induction of proinflammatory cytokine 
production in the heart or increased systemic proinflammatory cytokine levels in 
patients with heart failure remain unknown. During the last years it was 
suggested that the heart possesses an innate stress program that is activated 
upon TLR stimulation in the heart (12). Interestingly, TLRs are upregulated in the 
heart in patients with idiopathic dilated cardiomyopathy (13). Hence, we decided 
to further address the role of MyD88 in the progression from autoimmune 
myocarditis to heart failure. 
TLR signalling is generally divided into two signalling pathways, MyD88 
dependent and MyD88 independent signalling (14). MyD88 independent 
signalling is mainly promoted by the TLR adaptor proteins TRIF and TRAM, 
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which induce amongst others the secretion of type I IFN (14). Members of the 
type I IFN family are major immune regulators and are already in use as 
therapeutic agents in autoimmune diseases, for example in Multiple Sclerosis or 
against chronic viral infection (15-17). On the other hand, type I IFN levels have 
been correlated with clinical manifestations of Systemic Lupus Erythematosus 
(SLE) (18) and Sjogren's syndrome (19). These studies highlight the complex 
role for type I IFN in the induction of autoimmune diseases with either protective 
or deteriorative function. Hence, the third part of my thesis was to determine the 
function of type I IFN in the induction of EAM.  We therefore took advantage of 
IFNαβR deficient mice, which are unable to signal both IFN-alpha and IFN-beta, 
to address the role of type I IFN signalling in EAM induction. We aim to better 
characterize the conditions necessary for the induction of autoimmunity. 
Understanding of these mechanisms is a prerequisite for the prevention of 
autoimmune diseases and the development of novel causal treatment strategies. 
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GENERAL INTRODUCTION 
 
Myocarditis 
Human disease 
Myocarditis is clinically defined as inflammation of the heart muscle (20). 
Epidemiological studies suggest that myocarditis is a major cause of sudden 
death in adults less than 40 years of age (21). Inflammatory lesions are often 
focal in nature, which complicates diagnosis of myocarditis. To resolve the 
problem of differences in methods of diagnostic evaluation, the “Dallas Criteria” 
for the histological diagnosis of myocarditis were introduced (22).  
In Europe and North America, myocarditis most often results from infections with 
enteroviruses such as coxsackievirus B3 or adenoviruses (20, 23, 24). But also 
cardiotropic bacteria such as Borrelia and Chlamydia can induce myocarditis and 
heart failure (25). A growing body of evidence suggests that myocarditis often 
results in dilated cardiomyopathy (DCM), which is the most common cause of 
heart failure in young patients (20, 26, 27).  
Notably, many of the affected patients with DCM develop heart-specific 
autoantibody responses suggesting a role for autoimmunity in disease 
pathogenesis (28, 29). Evidence for autoimmunity in postviral cardiomyopathy 
also results from the observations of abnormal expression of HLA class II on 
endothelial cells and from the weak but significant association of dilated 
cardiomyopathy with HLA-DR4 (30). Further, immunosuppressive therapy can 
improve heart function in some patients, particularly in individuals without 
evidence for persistence of viral or bacterial genomes in heart biopsies (26, 31, 
32). These observations suggest that post-infectious autoimmunity might play an 
important role in disease development (33, 34).  
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Mouse models of autoimmune heart disease 
The idea that autoimmune mechanisms contribute to the development of 
myocarditis is additionally supported by experimental findings based on animal 
models. In several susceptible mouse strains such as BALB/c, A/J or SJL mice, 
enteroviral infections result in chronic myocarditis progressing to heart failure, 
even after clearance of the pathogen (35, 36). This chronic myocarditis following 
enterovirus infection is T-cell mediated because adoptive transfer of T-cells, but 
not serum from diseased mice, induces myocarditis in severe combined 
immunodeficiency (SCID) mice. Interestingly, peripheral blood lymphocytes from 
patients with dilated cardiomyopathy could adoptively transfer disease to SCID 
mice lacking B- and T-cells (37).  
 
In autoimmune myocarditis, several key questions remain unanswered. What 
promotes the generation of self-reactive T-cells in the context of infections with 
cardiotropic microorganisms? Why are some individuals more susceptible than 
others? What are the risk factors that define the possibility of an individual to 
develop chronic myocarditis progressing to dilated cardiomyopathy? In order to 
answer these questions and to design novel therapeutic strategies against 
postinflammatory cardiomyopathy, researchers take advantage of murine 
disease models. In fact, the genetic tractability of the mouse immune system has 
made the study of mouse models of cardiac autoimmunity an emerging area of 
interest. 
 
If chronic myocarditis resulting from infections is indeed autoimmune mediated, 
the question arises whether myocarditis can be induced experimentally by 
immunization with heart-specific self-antigens only. Immunization models offer 
the advantage of studying disease pathogenesis in vivo in the absence of 
infection. Neu and co-workers indeed showed that immunization of susceptible 
mice with heart specific alpha-myosin together with strong immunostimulants 
induces heart specific inflammation (Experimental Autoimmune Myocarditis = 
EAM) (38). EAM is a CD4+ T-cell mediated disease (33, 34, 39) and the 
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pathogenic cardiac alpha-myosin heavy chain epitopes mediating myocarditis 
have been mapped for BALB/c and A/J mouse strains (40, 41). In contrast to 
whole myosin, alpha-myosin-peptide immunization results in higher disease 
scores in BALB/c mice. Histological inflammation scores usually peak 3 weeks 
after the first alpha-myosin immunization and many animals develop ventricular 
dilation and heart failure. Of note, impaired cardiac contractility in immunized A/J 
and BALB/c strains correlates with the extent of CD4+ T-cell infiltrations in the 
heart (42).  
Antigen presenting cells, especially dendritic cells, play a crucial role in induction 
of autoimmune diseases (43, 44). Urs Eriksson and co-workers developed a 
method where activated bone marrow dendritic cells loaded with a heart muscle-
specific self peptide induces CD4+ T-cell mediated autoimmune myocarditis (45).  
Despite the fact that heart specific autoantibody responses parallel experimental 
autoimmune myocarditis, B-cell deficient mice on the BALB/c background are not 
protected from autoimmune myocarditis (4, 46). This latter finding clearly shows 
that autoantibodies and B-cells are not required for autoimmune myocarditis 
induction in most mouse strains. Autoantibodies against cardiac troponin I, 
however, contribute to the development of spontaneous heart failure in mice 
lacking the programmed cell death-1 (PD-1) immunoinhibitory co-receptor (47).  
So far, several transgenic mouse models for autoimmune myocarditis have been 
developed. Immunization with human  lpha-myosin peptides induces CD4+ 
mediated myocarditis in transgenic mice co-expressing human hCD4 and HLA-
DQ6 (48). This finding fits the observation that HLA-DQ6 is epidemiologically 
linked to enhanced susceptibility to dilated cardiomyopathy. Other transgenic 
mouse models are based on the expression of ovalbumin or beta-galactosidase 
in cardiomyocytes and/or smooth muscle cells (49, 50). These rather artificial 
models are useful studying CD8+ T-cell mediated myocyte specific inflammation 
but do not reflect the crucial contribution of CD4+ T-cells in the induction of heart-
specific autoimmunity.  
Proinflammatory cytokines are key players in the induction of myocarditis and 
DCM. Amongst others, TNF-alpha is also involved in the pathogenesis of 
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autoimmune myocarditis and heart failure. Cardiac-specific overexpression of 
tumour necrosis factor-alpha causes lethal myocarditis in transgenic mice (51). 
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This section will review parts of the innate immune system with focus on the Toll-
like Receptors (TLRs), including its adaptor protein MyD88 and the induction of 
type I IFN. For more comprehensive overview of the innate immune system I 
recommend the lecture of “ImmunoBiology, the immune system in health and 
disease” (52). 
 
Toll-like Receptors 
In 1993, Charles A. Janeway, Jr. wrote an article called “How the immune system 
recognizes invaders” (53). He predicted the existence of receptors of the innate 
immune system that would recognize pathogen-associated molecular patterns 
and would signal activation of the adaptive immune system. Now, 14 years later, 
we know he was right. 
Toll, the founding member of the TLR family was first described in Drosophila 
and plays a critical role in the antifungal response (54). To date, 12 members of 
the TLR family have been identified in mammals (55) (Table 1). TLRs are type I 
integral membrane glycoproteins characterized by the extracellular domains 
containing leucine-rich-repeat motifs and a cytoplasmic signalling domain 
homologous to that of the interleukin 1 receptor, termed the Toll/IL-1R homology 
(TIR) domain (56). TLRs are germline-encoded pattern-recognition receptors 
(PRRs) recognizing pathogen-associated molecular patterns (PAMPs). TLRs are 
evolutionarily conserved from the worm Caenorhabditis elegans to mammals. 
The main function of TLRs is the detection of invading microorganisms. 
Individual TLRs recognize distinct PAMPs that have been evolutionary conserved 
in specific classes of microbes. TLRs sense lipopolysacharide (LPS) (detected by 
TLR4), bacterial lipoproteins and lipoteichoic acids (detected by TLR2), flagellin 
(detected by TLR5), the unmethylated CpG DNA of bacteria and viruses 
(detected by TLR9), double stranded RNA (detected by TLR3) and single-
stranded viral RNA (detected by TLR7) (Table 1) (57).  
 10 
 
Table 1: TLR Recognition of microbial Components  
   
Microbial components  Species TLR 
Bacteria     
LPS Gram-negative bacteria TLR4 
Diacyl lipopeptides  Mycoplasma TLR6/TLR2 
Triacyl lipopeptides Bacteria and mycobacteria TLR1/TLR2 
LTA Group B Streptococcus TLR6/TLR2 
PG Gram-positive bacteria TLR2 
Porins Neisseria TLR2 
Lipoarabinomannan Mycobacteria TLR2 
Flagellin Flagellated bacteria TLR5 
CpG-DNA Bacteria and mycobacteria TLR9 
ND Uropathogenic bacteria TLR11 
Fungus     
Zymosan Saccharomyces cerevisiae TLR6/TLR2 
Phospholipomannan Candida albicans TLR2 
Mannan Candida albicans TLR4 
Glucuronoxylomannan Cryptococcus neoformans TLR2 and TLR4 
Parasites     
tGPI-mutin Trypanosoma TLR2 
Glycoinositolphospholipids Trypanosoma TLR4 
Hemozoin Plasmodium TLR9 
Profilin-like molecule Toxoplasma gondii TLR11 
Viruses     
DNA Viruses TLR9 
dsRNA Viruses TLR3 
ssRNA RNA viruses TLR7 and TLR8 
Envelope proteins RSV, MMTV TLR4 
Hemagglutinin protein Measles virus TLR2 
ND HCMV, HSV1 TLR2 
Host     
Heat-shock protein 60, 70  TLR4 
Fibrinogen  TLR4 
ND = not determined adapted from (14)  
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The Toll-like Receptor family can be further divided into subfamilies, each of with 
recognizes related PAMPs: The subfamily of TLR 3, 7, 8, and 9 are specialized 
on the detection of viruses and nucleic acids, that are unique to the microbial 
world. These TLRs are localized to intracellular compartments. TLR1, 2, 4, 5 and 
6 seem to mainly specialize in the recognition of bacterial products and are 
expressed on the cell surface.  
In addition to ligand specificity, the functions of individual TLRs differ in their 
expression patterns and the signal transduction pathways they activate. The 
expression of TLR is dependent on the cell type and is modulated during an 
ongoing immune response. TLR expression has been described for various 
immune cells, including macrophages, dendritic cells, B-cells and T-cells, as well 
as non-immune cells like fibroblast, epithelial cells or cardiomyocytes express 
TLRs (56, 58, 59).  
 
TLR signalling 
Stimulation of TLRs by microbial components triggers expression of several 
genes that are involved in immune responses. After ligand binding, TLRs 
dimerize and undergo conformational changes. It was shown that TLR2 forms 
heterodimers with TLR1 or 6, but in other cases TLRs are believed to form 
homodimers (58, 60). 
All TLR family members share homology in the cytoplasmic domains. In 
particular, a high degree of similarity exists within the Toll/interleukin-1 receptor 
(TIR)-domain. Signalling from TLRs involves the TIR domain of the receptor that 
recruits TIR-domain-containing adaptor molecules to the TIR domain of the TLR. 
So far, five TLR adaptor molecules have been described: myeloid differentiation 
primary-response protein 88 (MyD88), TIR-domain-containing adaptor protein 
(TIRAP) also named MAL, TIR-domain-containing adaptor protein inducing IFN-
beta (TIRF) also named TICAM1, TRIF-related adaptor molecule (TRAM) and 
sterile alpha- and armadillo-motif-containing protein (SARM) (61). MyD88 is 
critical for the signalling of all TLRs except TLR3. A MyD88 dependent pathway 
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is analogous to IL-1R signalling (Figure 1). Upon stimulation, MyD88 associates 
with the cytoplasmic portion of TLRs and then recruits IL-1R-associated kinase 4 
(IRAK-4) and IRAK-1 through homophilic interaction of death domains. 
Subsequently, IRAK-4 associates with TNFR-associated factor 6 (TRAF6) and 
initiates downstream activation of the transcription factor NF- B and MAP 
kinases JNK and p38, resulting in induction of genes like proinflammatory 
cytokines involved in inflammatory responses and the induction of adaptive 
immunity (Figure 1). 
 
TLR stimulation induces Type I IFN 
Among the key requirements for the induction of adaptive immunity is the 
upregulation of costimulatory molecules (including but not limited to CD80 and 
CD86) on antigen-presenting cells (APCs) to stimulate T-cells. It is now clear, 
that the key event in upregulation of costimulatory molecules is the activation of a 
type I IFN response (62, 63). Interferon’s, first discovered by Isaacs (1957), are a 
family of cytokines which act early in the innate immune response (64). Within 
the TLR family, TLR3, 4, 7 and 9 stimulation, but not TLR2 ligand stimulation, 
induces type I IFN production.  
In general, type I IFN induction is shown to be MyD88 independent. MyD88 
independent TLR signalling is initiated by the TLR-adaptor molecules TRIF and 
TRAM (65, 66). TRAM is specifically involved in TLR4 signalling whereas TRIF 
interacts with several TLRs. It is suggested that TRAM acts as a bridging adaptor 
between TLR4 and TRIF (Figure 1). TRIF activation leads to the induction of a 
signalling cascade activating IRF-3 and IRF-7. These transcription factors form 
homodimers, resulting in the expression of a set of IFN-inducible genes. IRF-3 
and IRF-7 are essential for the production of type I IFN. The activity of these 
products leads to the maturation of APCs, expression of costimulatory molecules 
and immune activation in general (65). Interestingly, IFN type I induction is not 
completely MyD88 independent. TLR9-mediated IFN-alpha secretion occurs in a  
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Figure1: TLR Signalling Pathway 
TLRs and IL-1R share common signalling pathways in general. Ligand stimulation recruits TIR-
domain-containing adaptors including MyD88 and TIRAP to the receptor, and subsequently 
induces the formation of a complex of IRAKs, TRAF6, and IRF-5. TRAF6 acts as an E3 ubiquitin 
ligase and catalyzes the K63-linked polyubiquitin chain on TRAF6 itself and NEMO with E2 
ubiquitin ligase complex of UBC13 and UEV1A. This ubiquitination activates the TAK1 complex, 
resulting in the phosphorylation of NEMO and activation of the IKK complex. Phosphorylated IκB 
undergoes K48-linked ubiquitination and degradation by the proteasome. Once freed, NF-κB 
translocates into the nucleus and initiates the expression of proinflammatory cytokine genes. 
Simultaneously, TAK1 activates the MAP kinase cascades, leading to the activation of AP-1, 
which is also critical for the induction of cytokine genes. TLR4 triggers the MyD88-independent, 
TRIF-dependent signalling pathway via TRAM to induce type I IFNs. TRIF activates NF-κB and 
IRF-3, resulting in the induction of proinflammatory cytokine genes and type I IFNs. TRAF6 and 
RIP1 induce NF-κB activation and TBK1/IKK-i phosphorylate IRF-3, which induces the 
translocation of IRF-3. Adapted from (55) 
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MyD88-dependent manner. Also in TLR7 and 8 signalling, MyD88 dependent 
pathways contribute at least partially to the activation of IRF-3 and subsequently 
of type I IFN (14). 
 
TLRs and autoimmunity 
The main function of TLRs is the induction of inflammation and adaptive 
immunity. It is well established that the co-administration of antigens together 
with TLR ligands induces not only local inflammation, but also an adaptive 
immune response against the antigen. This process has been named the 
adjuvant effect. The most potent adjuvant currently used in experimental 
immunology is the complete Freund`s adjuvant (CFA). CFA consist of heat 
inactivated Mycobacterium tuberculosis H37Ra suspended in paraffin oil. CFA 
induces a strong T-cell immune response that can, if co-administered with a 
potent auto-antigen, break tolerance and induce autoimmunity. Several murine 
models for human autoimmune diseases are based upon these properties 
including Experimental Autoimmune Encephalomyelitis (EAE), Experimental 
Autoimmune Uveitis (EAU) and Experimental Autoimmune Myocarditis (EAM).  
In EAE and EAU, the role of several TLR members has been investigated. EAE 
induction has been shown to be completely dependent on the TLR adaptor 
molecule MyD88 whereas TLR9 has at least a modulatory potential (67). In EAU, 
single TLR deficiencies for TLR2, 4 or 9 have no effect on disease induction 
whereas MyD88 or IL-1R deficiency completely prevents disease induction (68). 
However, the role of TLRs in autoimmune diseases is not limited to the process 
of disease induction. TLR signalling has immunomodulatory potential and can 
directly influence the progression and outcome of autoimmune diseases. For 
example, TLR3-ligand administration has been shown to induce endogenous 
IFN-beta production that protects from EAE (69). In additional, Lang et al. 
demonstrated that TLR ligands could act directly on beta islet cells to up-regulate 
MHC I and enhance autoimmunity (70). Very recently it was shown in the model 
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of EAM that systemic TLR9-dependent CpG administration can restore T-cell 
proliferation and overcome disease resistance in PKC-theta deficient mice (71). 
Thus far, diseases discussed are all T-cell mediated, however TLRs also play a 
major role in the pathogenesis of B-cell mediated autoimmune disease, namely 
Systemic Lupus Erythematosus (SLE) or Sjogren’s syndrome (72). Both, DNA- 
and RNA-containing immune complexes have been shown to stimulate the 
production of autoantibodies through TLR7 and TLR9 in SLE or Sjogren’s 
syndrome (73). 
 
TLRs in the heart 
Myeloid cells express TLRs but TLRs are also expressed in tissues without a 
recognized immune function, notably the heart and vasculature (59). 
Remarkably, TLR4 expression is increased in the heart of patients with dilated 
cardiomyopathy (13). In general, TLR2, 3, 4, 5 and 6 expression can be detected 
on cardiomyocytes and ligand activation of TLR2, TLR4 and TLR5 in cultured 
cardiomyocytes resulted in NF-κB activation and the expression of the 
inflammatory cytokine IL-6, the chemokine MIP-2 and the cell surface adhesion 
molecule ICAM-1 (59, 74). Furthermore, in a model of CVB3 induced 
myocarditis, it has been shown that MyD88 expression is upregulated during 
disease course in the heart (75). 
Recent findings from mouse models of myocardial infarction show a role for 
TLR4 and TLR2 in the remodelling process after myocardial injury. Remodelling 
is a very complex process that induces changes in cardiac shape, size and 
composition in response to myocardial injury. It was shown, that TLR2 deficient 
and TLR4 deficient mice show higher survival, reduced inflammation, reduced 
myocardial fibrosis and improved heart function after myocardial infarction 
compared to control mice (76, 77). The exact mechanism that describes how 
TLR signalling influences cardiac remodelling and survival is not yet resolved. 
Due to the absence of infections, it is suggested that endogenous TLR ligands in 
 16 
 
the heart might contribute to the remodelling and the pathogenic process of heart 
failure (77).  
TLR stimulation could also boost heart failure by induction of proinflammatory 
cytokine secretion in the heart (12, 78). Proinflammatory cytokines are believed 
to be key players in the induction and progression of heart failure (79). Patients 
with chronic heart failure are characterized by systemic inflammation, as evident 
by raised circulating levels of inflammatory cytokines and chemokines (78). 
Furthermore, several studies have reported that the increased plasma levels of 
inflammatory cytokines correlate with deterioration of cardiac function (9, 11). 
The “cytokine hypothesis” for heart failure suggests that heart failure progresses 
as a result of the toxic effects exerted by endogenous cytokine cascades on the 
heart and peripheral circulation (80). Importantly, the myocardium itself may 
represent an important source of proinflammatory cytokines (81, 82). Amongst 
others, cytokines identified to contribute to heart failure also include TNF-alpha, 
IL-6 and IL-1, which are all members of the innate immune system (6). 
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Materials and Methods 
 
Mice 
MyD88ko (83) mice backcrossed for more than 9 generations on a H-2d (BALB/c) 
background were kindly provided by Professor Shizuo Akira, Osaka, Japan. 
IFNαβRko mice backcrossed for > 6 generations on a H-2d (BALB/c) background 
were generated as described (84) and kindly provided by Professor Christian 
Bogdan, Freiburg, Germany. Depending on the experiment, wild-type BALB/c 
mice or heterozygous littermates from in-house breeding were used as controls. 
Experiments were in accordance with Swiss federal legislation and had been 
approved by the local authorities. 
 
Generation of bone marrow chimeric mice  
6- to 8-week-old recipient mice were reconstituted with bone marrow (bm) cells 
derived from tibiae and femurs from the respective donors. Bm cells (15 x 106 
cells) were injected into the tail veins of recipients 24 hours after whole-body 
irradiation (2 x 250rad). 
 
Induction of Experimental Autoimmune Myocarditis 
Mice, older than 8 weeks were used for EAM experiments. For each mouse, 
150µg murine alpha-myosin-heavy chain peptide (MyHC-alpha Ac-
RSLKLMATLFSTYASADR-OH) (ANAWA Trading SA) was dissolved in 100µl 
complete Freund`s adjuvant (CFA) (Difco, 231131) and emulsified 1:1 with 100µl 
sterile PBS. For the preparation of the emulsion, a system with two 2ml luer-lock 
syringes (Braun Omnifix, 4617029V) was used. One syringe filled with CFA-
MyHC the other syringe with the appropriate volume of PBS. The emulsion 
process was started pressing the PBS over a three-way stopcock (BD Connecta 
Plus 3, 394601) into the MyHC-CFA. After several minutes of intense mixing, an 
increase of resistance occurs indicating the successful completion of the MyHC-
CFA emulsion. Each mouse was injected with a final volume of 200µl MyHC-CFA 
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emulsion on days 0 and 7. Depending on the experiment, mice were sacrificed 7, 
14, 21 or 28 days after the first immunization.  
 
Immunization with bone marrow derived dendritic cells 
For the generation of bone marrow dendritic cells (bmDCs), whole bone marrow 
isolated from femur and tibiae was plated on several bacterial quality petri dish 
(Falcon, 100x15mm style, 351029) at a density of two-million cells per dish in 
10ml bmDC medium (bmDC medium: RPMI 1640 (Bio-Whittaker, BE12-115F, 
containing 25mM HEPES and L-Glutamine) supplemented with 10% FCS, 
Pen/Strept (1/100, Gibco 15140-122), β−Mercaptoethanol (1/1000, Gibco 31350-
010), Sodium Pyruvate (1/100, Gibco 11360-039), Non-Essential Amino Acids 
(1/100, Gibco 11140-035) and 200U/ml rmGM-CSF (Peprotech)).  
After 8 days culturing, bmDCs were loaded with MyHC-alpha 10µg/ml for 1 hour 
and activated for additional 2 hours with 0.1µg/ml LPS (List Biological 
Laboratories INC Cat: 421) and 5 g/ml anti-CD40 (BD Pharmingen Cat: 
553787). BmDCs were then harvested in ice cold PBS and 500’000 bmDCs per 
mouse were i.p. injected. BmDC immunization was performed two times on day 0 
and 2. Mice were sacrificed 10, 15, 20, or 120 days after immunization 
depending on the goal of the experiment. 
 
bmDC/CFA combined “double immunization” 
For induction of myocarditis associated with strong fibrosis and heart dilation, 
mice were immunized with bmDCs on day 0 and 2 as described above and were 
additionally immunized with MyHC-CFA on day 10 and 17. Mice were sacrificed 
on day 31 and analyzed for myocarditis and fibrosis in the heart. 
 
MyHC-alpha specific CD4+ T-cell transfer. 
CD4+ T-cells were isolated with magnetic beads (CD4+ T-cell isolation kit; 
Miltenyi Biotech GmbH) from diseased wt BALB/c mice d14 after MyHC-CFA 
immunization and cultured on irradiated (2000rad) wt BALB/c splenocytes at a 
1:4 ratio in the presence of 2 µg/ml MyHC-alpha in RPMI 1640 complete medium 
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(RPMI 1640 (Bio-Whittaker, BE12-115F, containing 25mM HEPES and L-
Glutamine), Pen/Strept (1/100, Gibco 15140-122), β−Mercaptoethanol (1/1000, 
Gibco 31350-010), Sodium Pyruvate (1/100, Gibco 11360-039), Non-Essential 
Amino Acids (1/100, Gibco 11140-035)), 10% FCS containing 10ng/ml rmIL-23 
(provided by Burkhard Becher, Zürich, Switzerland) for 7 days. Cells were then 
washed and cultured in the presence of 20 U/ml of recombinant mouse IL-2 
(Peprotech) and 10ng/ml rmIL-23 without MyHC-alpha peptide for an additional 7 
days. This pulse/rest cycle was repeated at least three times. Finally, CD4+ T-
cells were restimulated for 4 days before i.p. injection of 3-6 x 106 CD4+ T-cells 
per syngeneic recipient. Mice were sacrificed 10 days after adoptive transfer. 
 
Histology 
Histological analysis was performed in collaboration with Professor Stephan 
Dirnhofer, University Hospital Basel and PD Michael Kurrer, University Hospital 
Zurich.  
After 24h fixation in 2% Paraformaldehyde-PBS, hearts were cut transversally 
into three pieces and embedded into paraffin. 5 µm thick sections were cut at 
various depths in the tissue section and stained with hematoxylin and eosin 
(H&E) to determine the level of inflammation. Myocarditis was scored using 
grades from 0 to 4 (0 - no inflammatory infiltrates; 1 - small foci of inflammatory 
cells between myocytes; 2 - larger foci of more than 100 inflammatory cells; 3 - 
more than 10% of a cross-section involved; 4 - more than 30% of a cross-section 
involved). 
Fibrosis was detected with Chromotrope-Anilin Blue (CAB) staining detecting 
Collagen deposition. Fibrosis was scored according to the same criteria as 
Myocarditis which are the following: from 0 to 4 (0, no collagen deposition; 1, 
small collagen deposition between myocytes; 2, larger collagen deposition of > 
5% of cross-section involved; 3, >10% of a cross-section involved; 4, >30% of a 
cross-section involved 
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FACS analysis  
Cells were stained using fluorochrome-conjugated mouse-specific antibodies 
purchased from BD Pharmingen. Samples were acquired on a FACS Calibur flow 
cytometer (BD Biosciences) or on a FACS Cyan (DakoCytomation). Data was 
analyzed using FlowJo (TreeStar) software. 
Surface molecules staining: Fc-receptors were blocked in staining buffer (PBS, 
1% FCS, 2mM EDTA) supplemented with 1% normal mouse serum for 15 
minutes at 4°C with an additional antibody staining at 4°C for 20 minutes. Cells 
were washed and resuspended in staining buffer and immediately analyzed.  
Intracellular staining: Before intracellular staining, cells were activated for 6 
hours with 20ng/ml phorbol myristate acetate (PMA) and 1 µM ionomycin in the 
presence of 10 µg/ml Brefeldin A. Surface molecules staining was performed as 
described above. Cells were then fixed in freshly prepared PBS containing 4% 
Paraformaldehyde (PFA) for 30 minutes at 4°C and then permeabilized and 
stained for intracellular components in PBS, 1% FCS, 2mM EDTA, 0.5% Saponin 
for 30 minutes at room temperature. Cells were then washed with staining buffer 
and immediately analyzed. 
 
bmDC migration assay 
Bone marrow Dendritic Cells (bmDCs) were harvested after 10 days in culture 
with bmDC medium as described above. bmDCs were resuspended in PBS 5% 
FCS at 10 x 106 cells/ml. bmDCs were stained for 5 minutes at room temperature 
in PBS 5% FCS 5µM CFSE. The presence of FCS is essential to buffer the toxic 
effect of CFSE. bmDCs are then washed in PBS 10% FCS. 20 million bmDCs 
are injected intraperitoneal in wt BALB/c mice or IFNαβRko mice. bmDC 
migration to the spleen and mesenteric lymph nodes was assessed 2 days after 
injection.  
 
Autoantibody ELISA 
96-well plates (Nunc 430341) were coated over-night with porcine myosin (sigma 
0-0531) 10 µg/ml in 0.1M NaHCO3 buffer pH = 9.6. Wells were then washed with 
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PBS pH = 7.4 Tween-20 0.05% and further blocked with PBS 2% BSA 0.05% 
Tween-20 for 2h at room temperature. Wells were then washed with PBS 0.05% 
Tween-20 and mouse sera was added in dilutions ranging from 1:160 to 1:20480 
in PBS, 2% BSA, 1% FCS, 0.05% Tween-20 for 2 h at room temperature. 
Wells were then washed with Tris Buffer (Tris 50 mM, NaCl 37 mM, KCl 2.7 mM). 
The following detection antibodies were added 1:2000 in Tris Buffer 2% BSA 
0.05% Tween-20): Goat anti-mouse total IgG AP (Southern Biotech 1030-04), 
Goat anti-mouse IgG 2b AP (Southern Biotech 1090-04), Goat anti-mouse IgG 
2a AP (Southern Biotech 1080-04), Goat anti-mouse IgG1 AP (Southern Biotech 
1070-04). Wells were washed with Tris buffer before Fluorescein diphosphate 
(FDP) substrate 10µM (Molecular Probes F2999) was applied for 1hour at room 
temperature. Fluorescence was measured at the following wavelengths: 
absorption 485 nm, emission 538 nm, cut off 530 nm. 
 
Whole splenocytes restimulation in vitro 
Whole splenocytes were isolated using 70µm cell strainers (BD Falcon Cat: 
352350). After red blood cell lysis in ACK-buffer (For 250ml: 2g NH4CL, 0.25g 
KHCO3, 0.005g EDTA), whole splenocytes were cultured in 96-well plates for 72 
hours with 0 - 10 µg/ml of MyHC-alpha peptide in RPMI 1640 complete medium 
(RPMI 1640 (Bio-Whittaker, BE12-115F, containing 25mM HEPES and L-
Glutamine), Pen/Strept (1/100, Gibco 15140-122), β−Mercaptoethanol (1/1000, 
Gibco 31350-010), Sodium Pyruvate (1/100, Gibco 11360-039), Non-Essential 
Amino Acids (1/100, Gibco 11140-035)) supplemented with 1% of normal mouse 
serum. 2 x 10-5 mmol 3H-Thymidine (5 x 10-4 mCi) (Amersham TRK120) was 
added per well for additional 10 hours. 3H-Thymidine incorporation was 
measured using Top Count NXT (Packard). 
 
CD4+ T-cell-proliferation 
CD4+ T-cells were isolated with magnetic beads (CD4+ T-cell isolation kit; 
Miltenyi Biotech GmbH) and cultured in 96-well plates for 72 hours on irradiated 
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(2000 rad) syngenic splenocytes, with 0-10 µg/ml of MyHC-alpha peptide in 
RPMI 1640 (Gibco) medium supplemented with 1% of normal mouse serum.  
Naïve CD4+CD62L+ T-cells were stimulated in 96-well plates with either 5 µg/ml 
soluble anti-CD3  antibody, 50 ng/ml PMA and 500 ng/ml Ionomycin, 1 µg/ml 
Concanavalin A (Con A) in the presence of irradiated wild-type DCs (1). 
Alternatively, naïve CD4+CD62L+ T-cells were stimulated with 1 µg/ml Con A on 
either MyD88+/+ or MyD88-/- DCs in the presence or absence of recombinant 
murine TNF-alpha (PeproTech) or a TNF-alpha blocking antibody. Proliferation 
was assessed by measuring 3H-thymidine incorporation. All reagents and media 
were endotoxin free. 
 
ReverseTranscription-PCR (RT-PCR) 
Hearts were isolated and homogenized with a Polytron PT 1200 CL (Kinematica) 
in 2ml Tri Reagent (Molecular Research Center, Inc.). mRNA was extracted with 
Bromochloropropane (Molecular Research Center, Inc.), precipitated in 
Isopropanol and washed in 70% Ethanol. Following resuspension, mRNA 
samples were treated with Deoxyribonuclease I (Fermentas, Cat: EN0521). 
cDNA was subsequently generated using RevertAid M-MuLV Reverse 
Transcriptase (Fermentas, Cat:EP0441). PCR from cDNA was performed using 
TaqPCR Master Mix Kit (Qiagen Cat:201445). PCR products were analyzed on a 
2% Agarose Gel (Invitrogen Cat:15510-027) containing 3µg Ethidiumbromide per 
100ml Gel in TAE-Buffer. Gels were run for 45 minutes at 100 Volts in a 
PowerPac Universal (Biorad) system. Levels of gene expression were analyzed 
with the ChemImager 5500 (Alpha Innotech). 
Primer sequences: 
IL-1beta forward:   5’-CAG GAT GAG GAC ATG AGC ACC-3’ 
IL-1beta reverse:   5’-CTC TGC AGA CTC AAA CTC CAC-3’ 
IL-18 forward:  5’-ACT GTA CAA CCG CAG TAA TAC GC-3’ 
IL-18 reverse:  5’-TCC ATC TTG TTG TGT CCT GG-3’ 
TNF-alpha forward:  5’-GGC AGG TCT ACT TTG GAG TCA TTG C-3’ 
TNF-alpha reverse:  5’-ACA TTC GAG GCT CCA GTG AAT TCG T-3’ 
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IL-6 forward:   5’-TTG CCT TCT TGG GAC TGA TGC-3’ 
IL-6 reverse:   5’-GTA TCT CTC TGA AGG ACT CTG G-3’ 
IFN-alpha forward:  5’-ATA ACC TCA GGA ACA ACA G-3’ 
IFN-alpha reverse:  5’-TCA TTG CAG AAT GAG TCT AGG AG-3’ 
IFN-beta forward:  5’-CCA CAG CCC TCT CCA TCA ACT ATA AGC-3’ 
IFN-beta reverse:  5’-AGC TCT TCA ACT GGA GAG CAG TTG AGG-3’ 
beta-Actin forward:  5’-TGT GAT GGT GGG AAT GGG TCA-3’ 
beta-Actin reverse:  5’-TTT GAT GTC ACG CAC GAT TTC C-3’ 
 
Echocardiography 
For echocardiography, mice were anesthetized with Isofluran (5% initially, 1-2% 
for maintenance) resulting in a stable heart rate of 180 to 200 beats per minute. 
In vivo cardiac function was analyzed using a 15.0 mHz linear transducer 
attached to a Philips echocardiography system (Philips Medical System, Zurich, 
Switzerland). With the mouse in the left lateral decubitus position, the transducer 
was placed on the left hemithorax. Care was taken to avoid excessive pressure, 
which can induce bradycardia. End-diastolic left-ventricular diameter (EDD), end-
systolic left-ventricular diameter (ESD) and ejection time were determined; end 
diastole being defined as the maximal left ventricle (LV) diastolic dimension and 
end systole as the most anterior systolic excursion of the LV posterior wall. The 
fractional shortening (FS) of the LV is expressed as a percentage as %FS=(EDD-
ESD)/EDDx100. The velocity of circumferential fibre shortening (Vcf) is 
expressed in (circ/s) and calculated as Vcf=(EDD-ESD)/(ejection time x EDD). 
 
Statistics  
Dichotomous data were analyzed by Fisher`s exact test. The Mann-Whitney U 
test was used for the evaluation of severity scores. Proliferation responses and 
cytokine levels were compared using ANOVA and the t-test. 
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Abstract 
Background: Experimental autoimmune myocarditis (EAM) is a CD4+ T-cell 
mediated mouse model of postviral cardiomyopathy. Activation of IL-1 type 1 and 
Toll-like receptors (TLR) sharing the common downstream adaptor molecule 
MyD88 is required for disease induction. The specific role of MyD88 in 
myocarditis, however, is not known. 
Methods and Results: In contrast to control littermates, MyD88-/- mice were 
protected from myocarditis after immunization with  -myosin heavy chain derived 
peptide (MyHC-alpha) and complete Freund`s adjuvant (CFA). Disease 
resistance of MyD88ko mice resulted from impaired expansion of heart-specific 
CD4+ T-cells after immunization. Intrinsic defects of MyD88ko CD4+ T-cells were 
excluded. In contrast, MyD88ko but not wt primary antigen presenting dendritic 
cells (DCs) were defective in their capacity to prime CD4+ T-cells. This defect 
mainly resulted from the inability of MyD88ko DCs to release TNF-alpha. The 
critical role of MyD88 signalling in DCs in the peripheral lymphatic compartments 
was finally proven by repetitive injection of activated, MyHC-alpha loaded wt DCs 
that fully restored T-cell expansion and myocarditis in MyD88ko mice.  
Conclusions: Autoimmune myocarditis induction depends on MyD88 signalling 
in self-antigen presenting cells in the peripheral compartments. We conclude that 
MyD88 might become a target for prevention of heart-specific autoimmunity and 
cardiomyopathy. 
 
Key words: myocarditis, cardiomyopathy, inflammation, autoimmunity, heart 
failure 
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Introduction 
Dilated cardiomyopathy is the most common cause of heart failure in young 
patients and often results from enteroviral myocarditis (20, 28). Many patients 
show heart-specific autoantibodies (28, 29), and/or upregulation of activation 
markers on heart infiltrating cells (32). Interestingly, patients with heart-specific 
autoantibodies but no evidence for viral genome persistence in heart biopsies 
show improvement of their cardiac function upon immuno-suppression (31). 
Therefore, it is reasonable to conclude that autoimmunity is involved in the 
pathogenesis of postinflammatory cardiomyopathy (for review, see (33, 34)).  
Animal models greatly advanced our knowledge on the pathogenesis of 
myocarditis and inflammatory cardiomyopathy. In susceptible mice, for example, 
infection with enteroviruses results in a biphasic myocarditis with an early acute 
stage 5-8 days after inoculation, followed by a chronic stage of low-grade 
inflammation (36). Interestingly, T-cells from mice with enteroviral myocarditis 
transfer disease in syngenic severe combined immunodeficiency (SCID) 
recipients lacking B- and T-cells, suggesting a crucial role for autoreactive T-cells 
in disease pathogenesis (85). Furthermore, immunization of susceptible mice 
with alpha-myosin derived peptides together with complete Freund`s adjuvant 
(CFA) results in CD4+ T-cell mediated experimental autoimmune myocarditis (33, 
34, 38).  
TLRs belong to the Toll-interleukin 1 receptor superfamily of conserved surface 
molecules triggering innate mechanisms of immunity upon stimulation with 
microbial products or endogenous danger signals (86, 87). In the context of 
inflammatory heart disease, it has been shown that Toll-like receptor 4 is 
expressed together with enteroviral replication in hearts from patients with dilated 
cardiomyopathy (88). In addition, mice lacking Toll-like receptor 4 develop 
markedly reduced myocarditis after infection with enteroviruses such as 
Coxsackie B3 (CVB3) (89). In the experimental autoimmune myocarditis model 
activation of Toll-like receptors on selfantigen presenting dendritic cells (DCs) is 
essential for the induction of myocarditis and heart failure (45). Furthermore, IL-1 
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type 1 receptor signalling on DCs is critical for autoimmune myocarditis 
development (1). During myocarditis development, recruitment of activated, bone 
marrow derived dendritic cells precedes the accumulation of macrophages and 
T-cells in the heart (90-92). Accordingly, disease induction by adoptive transfer of 
heart-specific CD4+ T-cells requires pretreatment of recipient mice with LPS and 
other strong Toll-like receptor stimulants upregulating MHC class II expression 
on heart resident DCs (91). 
MyD88 is an essential adaptor molecule that mediates complex proinflammatory 
pathways involving a cascade of kinases integrating both Toll-like receptor 4 and 
IL-1 receptor type 1 activation (87). Its role in autoimmune heart disease is not 
known yet.  
To assess the role of MyD88 in the expansion of heart-specific CD4+ T-cells and 
the development of autoimmune heart disease, we assessed myocarditis 
susceptibility of mice genetically lacking MyD88. Here we describe that MyD88 is 
required for myocarditis induction after MyHC-CFA immunization. More 
specifically, we found that MyD88 signalling in dendritic cells is essential to prime 
heart specific CD4+ T-cells in vivo.  
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Methods 
 
Mice. MyD88ko mice were generated as described (83) and backcrossed for > 9 
generations on a H-2d (BALB/c) background. Wild-type or heterozygous 
littermates were used as controls. Experiments were in accordance with Swiss 
federal legislation or Austrian law, and had been approved by the local 
authorities.  
 
Myocarditis induction. Mice were injected subcutaneously with 100 g/mouse of 
the murine  -myosin-heavy chain peptide (MyHC-alpha: Ac-
RSLKLMATLFSTYASADR-OH) emulsified 1:1 with complete Freund`s adjuvant 
(CFA) on days 0 and 7 (4, 38). For myocarditis induction using dendritic cells 
(DCs), immature DCs were pulsed with MyHC-alpha and activated for 2 hours 
with 0.1  g/ml of LPS and 5  g/ml of anti-CD40 prior to intraperitoneal injection 
of 250000 DCs per mouse three times every second day. For adoptive transfer, 
we injected intraperitoneally 107 MyHC-alpha specific in vitro restimulated CD4+ 
T-cells per mouse. Depending on the experiment, mice were sacrificed after 10, 
14, 21, or 28 days.  
 
Histopathology. Myocarditis was scored using grades from 0 to 4 (0 - no 
inflammatory infiltrates; 1 - small foci of inflammatory cells between myocytes; 2 - 
larger foci of more than 100 inflammatory cells; 3 - more than 10% of a cross-
section involved; 4 - more than 30% of a cross-section involved) (1, 45).  
 
Dendritic cells. For immunization experiments, bone marrow derived DCs were 
generated as described (45). Naïve, primary DCs were obtained from lymph 
nodes and spleens of non-immunized mice. Alternatively, we isolated DCs from 
draining lymph nodes 24 hours after MyHC-CFA immunization using magnetic 
beads (MACS DC isolation kit, Miltenyi Biotech GmbH) and cell sorting. For 
analysis of surface molecules, DCs were preincubated for 30 min at 4° with 1% 
normal mouse serum in staining buffer (Pharmingen) before staining with the 
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appropriate fluorochrome labelled antibodies from Pharmingen. Viable cells were 
assessed in FACS scatter plots by gating on Propidium Iodine negative 
populations. For cytokine analysis, primary DCs were plated at 1 x 106/ml in 96 
well plates and activated with LPS at 0.1  g/ml.  
 
Cytokine analysis. Cytokine levels were measured in culture supernatants using 
commercially available Quantikine ELISA kits (R&D Biosystems, Minneapolis, 
U.S.A). 
 
Autoantibodies. We assessed antibody responses against whole alpha-myosin 
with an ELISA as described (45), using AP-labelled goat anti-mouse IgG 
subclass antibodies (Southern Biotechnology Associates). Antibody titers were 
determined at half maximum OD405nm. 
 
CD4+ T-cell-proliferation. CD4+ T-cells were isolated with magnetic beads (CD4+ 
T-cell isolation kit; Miltenyi Biotech GmbH) and cultured in 96-well plates for 72 
hours on irradiated (2000 rad) syngenic splenocytes, with 0.01-10  g/ml of 
MyHC-alpha peptide in RPMI 1640 (Gibco) medium supplemented with 1% of 
normal mouse serum.  
Naïve CD4+CD62L+ T-cells were stimulated in 96-well plates with either 5  g/ml 
soluble anti-CD3  antibody, 50 ng/ml PMA and 500 ng/ml Ionomycin, 1  g/ml 
Concanavalin A (Con A) in the presence of irradiated wild-type DCs (16). 
Alternatively, naïve CD4+CD62L+ T-cells were stimulated with 1 mg/ml Con A on 
either wt or MyD88ko DCs in the presence or absence of recombinant murine 
TNF-alpha (PeproTech) or a TNF-alpha blocking antibody. Proliferation was 
assessed by measuring (3H)-methyl-thymidine incorporation. All reagents and 
media were endotoxin free. 
 
Statistics. Dichotomous data were analyzed by Fisher`s exact test. The Mann-
Whitney U test was used for the evaluation of severity scores. Proliferation 
responses and cytokine levels were compared using ANOVA and the t-test.  
 30 
 
Results  
Myocarditis induction requires MyD88 signalling  
In order to define the role of MyD88 signalling in autoimmune myocarditis we first 
compared myocarditis susceptibility of mice lacking MyD88, heterozygous 
MyD88+/-, or MyD88+/+ (wt) littermates. As illustrated in figure 2A (right panel), 
figure 1C, and summarized in table 2, both wild-type littermates and MyD88+/- 
mice developed severe myocarditis with inflammatory infiltrates containing 
granulocytes, eosinophils, and mononuclear cells including macrophages and 
lymphocytes after two immunizations with MyHC-CFA. In contrast, MyD88ko 
mice were protected from disease, and developed minimal pericardial 
calcifications only (Figure 2A, left panels; Fig 2C; table). Differences in disease 
susceptibility between MyD88ko and MyD88+/- and wt mice were consistently 
observed at different time points, i.e. 14, 21 or 28 days after immunization (not 
shown). Therefore, the adaptor molecule MyD88 is crucial for the induction of 
autoimmune myocarditis after immunization with cardiac selfantigen together with 
CFA. 
 
Impaired expansion of heart-specific CD4+ T-cells in MyD88ko mice 
Autoimmune myocarditis is a CD4+ T-cell mediated disease (33, 45). In mice 
lacking MyD88, disease resistance paralleled impaired expansion of heart-
specific T-cells, as suggested by the impaired in vitro proliferation of MyHC-alpha 
restimulated whole splenocytes (Figure 3A) and – more specifically - by the 
absence of in vitro proliferation of MyD88ko but not wt CD4+ T-cells restimulated 
with MyHC-alpha pulsed irradiated splenocytes (Figure 3B). Accordingly, the 
production of IFN-gamma was reduced in supernatants of in vitro restimulated 
whole splenocytes from MyD88ko but not wt  mice (Figure 3C). IL-4 levels, on the 
other hand, were uniformly low in supernatants from both, in vitro restimulated wt 
and MyD88ko splenocytes. Regarding humoral autoimmunity, MyD88ko mice still 
mounted myosin specific IgG autoantibodies upon immunization, albeit at 
significantly lower IgG1 titers. IgG2a and IgG2b anti-myosin responses, on the  
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Figure 2: Myocarditis susceptibility of MyD88ko mice 
(A) MyD88ko mice are protected from autoimmune myocarditis after MyHC-CFA immunization. 
Some MyD88ko mice develop minimal pericardial inflammation and calcifications (arrow) but no 
cardiac infiltrates (left panels). In contrast, wt mice develop severe myocarditis with inflammatory 
infiltrates surrounding necrotic cardiomyocytes (arrow).  
(B) Immunization with activated, MyHC-alpha loaded DCs restores myocarditis in both, MyD88ko 
(left panel) and wt (right panel) recipient mice. All sections were stained with Hematoxylin and 
Eosin. 10 x, or 200 x original magnifications are shown. 
(C) Disease severity scores of individual wt (filled squares) and MyD88ko (open circles) mice 
after either MyHC-CFA immunization, adoptive transfer of heart-specific wt CD4+ T-cells, or after 
immunization with activated, MyHC-alpha loaded wt DCs. 
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Figure 3 
Impaired CD4+ T-cell expansion and autoantibody production in MyD88ko mice 
(A) Impaired proliferation of in vitro MyHC-alpha restimulated splenocytes from MyD88ko mice 
(open triangles) compared to wt mice (filled squares), 21 days after immunization with MyHC-
alpha and CFA. Proliferation was assessed by measurement of 3H-Thymidine incorporation. 
Mean +/- SD of cpm values from 4-5 individual mice are shown.  
(B) Impaired proliferation of in vitro MyHC-alpha restimulated CD4+ T-cells from MyD88ko and wt 
mice. CD4+ T-cells were isolated 21 days after immunization and restimulated on irradiated 
syngenic splenocytes. Mean +/- SD of cpm values from 5 individual mice are shown. 
(C) Mean +/- SD of IFN-gamma and IL-4 in culture supernatants of MyHC-alpha restimulated 
whole splenocytes from MyHC-CFA immunized wt (black bars) vs. MyD88ko (white bars) mice. 
Each bar represents data from 5 individual mice. 
(D) Impaired humoral IgG subclass responses to whole myosin of MyHC-/CFA immunized 
MyD88ko (open circles) vs. wt (filled circles) mice. 
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other hand, were markedly impaired in MyD8ko mice (Figure 3D). Taken 
together, the absence of MyD88 signalling impairs both, the expansion of heart-
specific CD4+ T-cells and the generation of heart-specific humoral autoimmunity. 
In conclusion, these findings strongly suggest impaired CD4+ T helper cell 
function in MyD88ko mice after immunization with cardiac selfantigen. 
 
MyD88 is not intrinsically required for CD4+ T-cell activation 
Next, we asked whether MyD88 signalling is intrinsically required for CD4+ T-cell 
activation. We isolated naïve CD62L+CD4+ T-cells from wt and MyD88ko mice 
and compared their primary response upon various stimuli. As illustrated in figure 
4, wt and MyD88ko CD4+ T-cells did not differ in their capacity to proliferate upon 
stimulation with anti-CD3ε or PMA/Ionomycin. Furthermore, there was no 
difference in the primary responses between wt and MyD88ko CD4+ T-cells upon 
stimulation with Concanavalin A (Con A) in the presence of irradiated wild-type 
antigen presenting cells. In conclusion, we found no in vitro evidence for impaired 
proliferation of MyD88ko CD4+ T-cells upon T-cell receptor stimulation (anti-
CD3ε), intrinsic activation (PMA/Inomycin), or antigen presenting cell dependent 
indirect activation (Con A and wild-type DCs) that would explain their impaired 
expansion in MyD88ko mice. 
 
Heart-specific wt CD4+ T-cells transfer myocarditis in MyD88ko recipients 
Both, IL-1 receptor type 1 and TLR receptors sharing the common adaptor 
molecule MyD88 are expressed in various tissues including leukocytes, 
endothelial cells, and cardiomyocytes (88). Therefore, the absence of MyD88 
might affect cardiac inflammation on many levels. Accordingly, we first asked 
whether heart-specific CD4+ T-cells and other inflammatory cells get at all access 
to the heart in MyD88ko mice. To address this question we first created a highly 
autoreactive and heart-specific CD4+ T-cell line. CD4+ T-cells were isolated from 
immunized wt mice and restimulated for several times in vitro with MyHC-alpha 
pulsed irradiated splenocytes. A prolonged resting phase followed each 
restimulation. The resulting CD4+ T-cell line was MyHC-alpha specific, and  
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Figure 4 
Primary responses of wt vs. MyD88ko CD4+ T-cells 
CD4+CD62L+ T-cells from naïve mice were stimulated with anti-CD3 , PMA/Ionomycin, or Con A 
in the presence of wild-type dendritic cells (DC). Proliferation was measured after 36 hours of 
culture. One out of several representative experiments is shown. 
 
Figure 5 
MyHC-alpha specific CD4+ T-cell line 
MyHC-alpha specific CD4+ T-cells showed vigorous proliferation upon in vitro MyHC-alpha 
restimulation on irradiated splenocytes (A), and produced high levels of IFN-gamma (B). 
 
produced high levels of IFN- amma upon restimulation (Figure 5A,B). Adoptive 
transfer of 107 activated, heart specific CD4+ T-cells per mouse induced 
myocarditis of similar prevalence albeit slightly reduced severity in both, wt and 
MyD88ko mice (Table 2). These findings suggest that MyD88 signalling is not 
decisive for the recruitment of autoreactive CD4+ T-cells to the heart during 
myocarditis development.  
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Table 2:  Myocarditis prevalence and disease severity in MyD88-/- mice and wild-type 
controls 
 
Mice   Treatments        Disease prevalence        Severity grade 
 [genotype]        [# diseased/ # treated]     [median (range)] 
 
MyD88-/-  MyHC-CFA (days 0,7)       2/ 8*     0    (0-1) 
MyD88+/+  MyHC-CFA (days 0,7)    11/13*     2    (0-3) 
 
MyD88-/-  (MyHC-alpha CD4+ T-cells    5/ 6     1.5 (0-3)† 
MyD88+/+  (MyHC-alpha CD4+ T-cells     6/ 6     3    (2-3)† 
 
MyD88-/-  MyHC-alpha pulsed dendritic cells  11/12     2   (0-4) 
MyD88+/+  MyHC-alpha pulsed dendritic cells    9/ 9     2   (2-3) 
 
*P < 0.03 MyD88-/-  vs. MyD88+/+ for comparison of disease prevalence 
†P= 0.08 MyD88-/- vs. MyD88+/+ for comparison of severity (Mann Whithney)
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MyD88ko DCs failed to prime wild-type CD4+ T-cell responses 
So far, our data suggest functionally intact CD4+ T-cells in MyD88ko mice and 
exclude a relevant role for MyD88 signalling in the recruitment of CD4+ T-cells to 
the heart. We, therefore, hypothesized that disease resistance of MyD88ko mice 
most likely results from the impaired capacity of antigen presenting cells to prime 
and expand autoreactive CD4+ T-cells in the peripheral compartments in vivo. 
We therefore assessed the functionality of MyD88ko DCs to promote primary T-
cell responses. To overcome the mechanisms of antigen processing and 
presentation we compared Con A induced proliferation of naïve wild-type CD4+ 
T-cells in the presence of either wt or MyD88ko DCs. In fact, primary Con A 
mediated CD4+ T-cell responses were significantly impaired in the presence of 
MyD88ko compared to wt DCs (Figure 6). The impaired functional capacity of 
MyD88ko DCs in peripheral lymph nodes, however, did not result from a defect in 
upregulation of essential costimulatory CD40, CD80, CD86, or MHC class II 
molecules because we found no difference in the expression of these surface 
molecules on dendritic cells isolated from draining lymph nodes after 
immunization (Figure 7A). In contrast, it is well established that MyD88ko DCs 
fail to produce relevant amounts of proinflammatory cytokines after maturation 
(3). Their impaired production in MyD88ko mice might contribute to the disease 
resistance on many levels including priming, expansion, and maintaining of 
autoreactive T-cells as well as suppression of regulatory T-cells. Given the fact, 
that a very short activation period with TLR stimulants is sufficient to render 
MyHC-alpha loaded DCs pathogenic (45), we assessed the production profiles of 
various cytokines and found that TNF-alpha, but not IL-6 or IL-12p40 production 
of primary wt DCs peak during the first 4 hours after TLR stimulation (not shown). 
As illustrated in Figure 7B, this early TNF-alpha production is markedly impaired 
in MyD88ko compared wt DCs. Given the central role of TNF-alpha in 
autoimmune myocarditis induction (34), we hypothesized that the absence of the 
early peak release of TNF-alpha from MyD88ko DCs might play an important role 
in the reduced capacity of MyD88ko DCs to prime naïve CD4+ T-cells. Indeed, in  
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Figure 6 
Primary responses of naïve CD4+ T-cells in the presence of wt vs. MyD88ko DCs  
(A) CD4+CD62L+ T-cells were purified from naïve mice and stimulated with 1  g/ml Con A on 
either wt or MyD88ko DCs for 36 hours before measurement of 3H-thymidine incorporation. Each 
value represents mean cpm values of four different culture wells. One out of several 
representative experiments is shown. 
 
vitro blocking of TNF-alpha markedly reduced Con A mediated proliferative 
responses of naïve wild-type CD4+ T-cells in the presence of wt DCs to the levels 
observed in the presence of MyD88ko DCs (Figure 7C). On the other hand, 
addition of recombinant mouse TNF-alpha restored Con A induced proliferative 
responses of naïve CD4+ T-cells in the presence of MyD88ko DCs (Figure 7C). 
Taken together, MyD88ko primary DCs are defective in their capacity to prime 
naive T-cell responses. Impaired early TNF-alpha release by DCs lacking MyD88 
might explain impaired T-cell priming.  
 
MyHC-alpha loaded activated DCs restore myocarditis in MyD88ko mice 
If myocarditis resistance of MyD88ko mice indeed results from the reduced 
priming capacity of MyD88ko antigen presenting DCs in the peripheral 
compartments, administration of activated MyHC-alpha loaded wt antigen 
presenting cells would restore CD4+ T-cell expansion and myocarditis 
susceptibility of MyD88ko mice. To test this hypothesis, we injected groups of 
MyD88ko and wt mice with mature, CD11c+CD11b+CD8α-, MyHC-alpha loaded 
wt DCs and compared disease susceptibility and the expansion of autoreactive  
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Figure 7 
Functional capacity of MyD88ko vs. wt dendritic cells 
(A) FACS analysis of MHC class II and costimulatory molecule upregulation on wt (black line) vs. 
MyD88ko (red line) DCs from draining lymph nodes after subcutaneous immunization with 
MyHC/CFA. Filled histograms represent control staining. Draining lymph nodes were removed 24 
hours after immunization and cell suspensions were immediately stained with the appropriate 
antibodies. Histograms were gated on CD11c+ live cells.  
(B) TNF-alpha production of primary wt (black bars) vs. MyD88ko (white bars) DCs during 4 hours 
stimulation with 0.1  g/ml LPS.  
(C) Primary responses of CD4+CD62L T-cells in the presence of wt (black bars) compared to 
MyD88ko (white bars) DCs after stimulation with 1  g/ml Con A, in the presence of either 100 
 g/ml TNF-alpha antagonist or 250 U/ml recombinant murine TNF-alpha. 3H-thymidine 
incorporation reflecting proliferation was measured and is expressed as mean +/- SD of cpm 
values of 4 different culture wells. One out of several representative experiments is shown. 
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CD4+ T-cells in wt vs. MyD88ko mice. Indeed, CD4+ T-cells isolated from both, 
MyD88ko and wt mice after DC immunization, resulted in comparable albeit only 
mild myopericarditis after adoptive transfer (Figure 8). Most importantly, however, 
both, MyD88ko and wt mice developed severe myocarditis of the same 
prevalence and severity after injection of activated, self-antigen loaded wt DCs 
(Figure 2B, Figure 2C and Table 2). We therefore conclude that autoimmune 
myocarditis resistance of MyD88ko mice indeed results from a priming defect on 
the level of antigen presenting cells. Furthermore, our findings prove that in the 
presence of activated and competent wt DCs, MyD88 deficiency does not affect 
the functional capacity of the lymphatic system to provide an environment that 
allows the generation of autoreactive T-cells and autoimmune heart disease. 
 
 
Figure 8  
Myocarditis after adoptive transfer of myosin-specific wt and MyD88ko CD4+ T-cells from 
dendritic cell immunized mice. 
Wt and MyD88ko mice were immunized with in vitro generated, activated and MyHC-alpha 
loaded wild-type dendritic cells. Then, CD4+ T-cells were isolated from mice with myocarditis, 
expanded in FCS free medium, and injected into wt and MyD88ko recipients. Because of 
technical reasons both, wt and MyD88ko T-cells were much less pathogenic if isolated from DC 
immunized mice. Nevertheless, adoptive transfer still resulted in mild myopericarditis and there 
was no difference in the pathogenicity of wt and MyD88ko T-cells. Representative Hematoxylin 
and Eosin stained sections of grade 1 myopericarditis are shown. (200 x original magnifications) 
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Discussion 
In the present study we demonstrated that MyD88 signalling is essential for the 
stimulation of selfantigen presenting DCs to induce heart-specific CD4+ T-cell 
responses in the peripheral compartments in vivo. In contrast, adoptive transfer 
of activated heart-specific autoreactive CD4+ T-cells induced myocarditis in 
MyD88 deficient mice, suggesting that MyD88 signalling neither affects CD4+ T-
cell recruitment, nor accumulation of other inflammatory cells to the heart. More 
specifically, our findings provide a proof of principle that the lymphatic system of 
MyD88 deficient mice is fully competent to allow the development of autoimmune 
CD4+ T-cell responses if it becomes substituted with appropriately activated self-
antigen loaded antigen presenting cells.  
In our experiments, we observed upregulation of costimulatory molecules on 
lymph node derived DCs after MyHC-CFA-immunization in both, MyD88ko and 
wt mice. These findings contrast the fact that the in vivo upregulation of 
costimulatory molecules is impaired in MyD88 deficient pulmonary DCs after Toll-
like receptor activation (93). Obviously, depending on their mode of generation in 
vitro or resident location in vivo, DCs have different capacities to engage MyD88 
dependent and MyD88 independent pathways in response to activation (93). On 
the other hand, lymph node derived DCs of MyD88ko mice showed markedly 
reduced production of proinflammatory cytokines, such as TNF-alpha or IL-12 
after Toll-like receptor stimulation. However, even in the absence of exogenous 
Toll-like receptor stimulants we found an impaired capacity of MyD88ko DCs to 
promote Con A induced primary T-cell responses. This defect mainly resulted 
from a lack of TNF-alpha production in MyD88ko DCs and might reflect the fact 
that Con A directly mediates MyD88 dependent proinflammatory pathways. 
Otherwise the priming defect of MyD88ko DCs might result from impaired IL-
1 eta mediated auto/paracrine activation of DCs because IL-1 type 1-receptor 
signalling involves MyD88 dependent proinflammatory cascades. Accordingly, it 
has recently been shown that IL-1 receptor type 1 deficient mice are protected 
from autoimmune myocarditis (1). The impaired capacity of MyD88 deficient DCs 
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to release specific cytokines certainly contributes to impaired T-cell priming and 
disease resistance in MyD88ko mice: TNF-alpha, IL-12p40, and IL-6 for 
example, are all essential for autoimmune myocarditis development (4, 5, 94).  
Microbial products such as LPS acting on TLR4, CFA predominantly activating 
TLR2 and TLR4, or endogenous danger signals (95, 96) are critical for the 
capacity of antigen presenting cells to build up effective T-cell responses and to 
suppress regulatory T-cells (97, 98). Autoimmunity develops if TLR activation 
coincides release and uptake of self-antigen in lymphatic organs of genetically 
susceptible individuals (45). In the absence of TLR activation, uptake of 
selfantigen by dendritic cells is supposed to result in tolerogenic rather than 
autoaggressive T-cell responses (99-101). Based on our data, we cannot entirely 
exclude that the presence of tolerogenic T-cell populations in MyD88ko mice 
contributes to their myocarditis resistance. However, it was not possible to 
overcome disease resistance of MyD88ko mice by depletion of CD25+ cells prior 
to immunization (Marty & Eriksson, unpublished).  
Development of autoimmune myocarditis requires the recruitment of 
inflammatory cells to the heart (91, 92). Interestingly, systemic activation of the 
innate immune system with TLR stimuli, such as LPS results in upregulation of 
activation markers and MHC class II molecules on heart resident cells (91). 
Furthermore, LPS injection results in relapses of inflammatory infiltrates and 
more rapid progression of heart failure in immunized mice (34, 42, 45). In the 
context of CVB3 mediated myocarditis, treatments with both, LPS (102) and IL-
1beta (103) enhances disease susceptibility of resistant mouse strains, most 
likely by activation of tissue resident dendritic cells. Based on these observations, 
one would expect that heart resident antigen presenting cells interact with 
autoreactive CD4+ T-cells promoting their local expansion and the recruitment of 
other inflammatory cells such as macrophages, B cells, and granulocytes (34). 
Given the fact that MyD88 is a crucial common adaptor molecule mediating both, 
TLR and IL-1 type 1 receptor activation (86, 87), it was tempting to speculate that 
MyD88 signalling might also be essential for the recruitment and activation of 
heart infiltrating cells. Our data, however, clearly show that MyD88 signalling is 
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not required for the development of cardiac infiltrates in the presence of activated 
autoreactive T-cells. In fact, adoptive transfer of activated autoreactive T-cells 
induced myocarditis in both, wt and MyD88ko recipient mice. These findings 
argue for MyD88 independent mechanisms mediating the recruitment of 
inflammatory cells to the target organ in the presence of activated heart specific 
T-cells. Such mechanisms might include for example, MyD88 independent TLR 
signalling pathways (65). 
Several studies suggested that the absence of MyD88 signalling on antigen 
presenting cells promotes default Th2 mediated immune responses in the 
presence of innate activation (104). Therefore, the question arises whether a 
possible Th1 to Th2 shift in MyD88ko mice might affect myocarditis susceptibility 
after MyHC-CFA immunization. In fact, our data show markedly impaired 
production of the Th1 cytokine IFN-gamma in MyD88ko compared to wt CD4+ T-
cells. Production of the Th2 cytokine IL-4, however, was uniformly low in both, wt 
and MyD88ko CD4+ T-cells, suggesting that the failure to produce IFN-gamma 
rather reflects impaired expansion of heart-reactive CD4+ T-cells than a relevant 
Th1 to Th2 shift in the MyD88ko mice.  
In conclusion, we found a crucial role for MyD88 in rendering antigen-presenting 
cells capable of priming heart specific autoreactive T-cells. In addition, we 
provide first and direct evidence that the absence of MyD88 signalling in the 
lymphatic microenvironment of MyD88ko mice does not affect the generation of 
autoimmune heart disease if they become substituted with functional and 
activated wt DCs. From the clinical point of view, our findings suggest that 
treatment strategies targeting MyD88 signalling might contribute to the 
development of novel preventive and vaccination strategies that block the 
development of heart specific autoimmunity in the presence of a strong systemic 
inflammatory response and self-antigen release following cardiac injury.   
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Introduction 
In the first part of my thesis I addressed the role of MyD88 in autoimmune 
myocarditis induction. I described that after bmDC immunization, MyD88 
deficient and wild-type mice developed autoimmune myocarditis of the same 
severity and prevalence. Both, wt and MyD88 deficient mice showed comparable 
inflammation and damage in the heart. Based on this phenotype I will now 
analyze the role of MyD88 in the progression of inflammatory heart failure. 
 
TLR signalling and heart failure 
Toll-like Receptors recognize invariant patterns shared by groups of 
microorganisms (14). However, the “Danger-Model” of immunity suggested by 
Polly Matzinger proposes that cell damage, rather than foreignness, is what 
initiates an immune response (95). This concept implicates that stress responses 
and cell damage due to tissue injury of any cause might activate the innate 
immune system even in the absence of infections. TLRs and its signalling 
components are also expressed within the heart (74). It is therefore likely that 
endogenous ligands secreted by damaged or stressed cells within the heart 
activate innate immune reactions through TLRs.  
Recent findings from myocardial infarction studies in mice show a role for TLR4 
and TLR2 in the remodelling process after myocardial injury (76, 77). 
Remodelling is a very complex process that induces changes in cardiac shape, 
size and composition in response to myocardial injury (80). It was shown that 
TLR2 deficient and TLR4 deficient mice show higher survival, reduced 
inflammation, reduced myocardial fibrosis and improved heart function after 
myocardial infarction compared to control mice (76, 77). The exact mechanism of 
how TLR signalling influences cardiac remodelling and survival remain elusive. It 
is suggested that endogenous TLR ligands in the heart might contribute to the 
remodelling and the pathogenic process of heart failure (77).  
TLR stimulation could also contribute to heart failure development by induction of 
proinflammatory cytokine secretion in the heart (12). Proinflammatory cytokines 
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are believed to be key players in the induction and progression of heart failure 
(79). The “cytokine hypothesis” for heart failure suggests that heart failure 
progresses as a result of the toxic effects exerted by endogenous cytokine 
cascades on the heart and peripheral circulation (80). Cytokines identified to 
contribute to heart failure are, amongst others, TNF-alpha, IL-6 and IL-1, namely 
all members of the innate immune system (78). 
Interestingly, the IL-1 Receptor belongs to the same receptor superfamily as the 
Toll-like Receptors. TLRs and IL-1R have a conserved region in their cytoplasmic 
tails, which is known as the Toll/IL-1R (TIR) domain (2, 14) (Figure 9). 
Stimulation of TLRs triggers the association of MyD88 that further transmissions 
signalling. MyD88 has been shown to be essential for the production of 
proinflammatory cytokines upon TLR stimulation (62). We therefore identified 
MyD88 as an interesting player in the process of cardiac remodelling. To address 
the role of MyD88 in the development of autoimmune heart failure, we assessed 
heart function of mice that genetically lack the MyD88 signalling molecule after 
bmDC induced heart failure. 
Here we describe for the first time, that MyD88 dependent proinflammatory 
cytokine induction and TLR signalling within the heart is involved in heart failure 
development. 
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Figure 9: TLR/IL-1R structure homology 
Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) have a conserved cytoplasmic 
domain that is known as the Toll/IL-1R (TIR) domain. The TIR domain is characterized by the 
presence of three highly homologous regions (known as boxes 1, 2 and 3). Despite the similarity 
of the cytoplasmic domains of these molecules, their extracellular regions differ markedly: TLRs 
have tandem repeats of leucine-rich regions (known as leucine rich repeats, LRR), whereas IL-
1Rs have three immunoglobulin (Ig)- like domains. In TLR/IL1R signalling, MyD88 couples 
receptor signals via TIR domain-TIR domain interactions and transmits down-stream signalling 
through its death-domain (DD). Adapted from (14)  
 
   48 
Results 
After wt bmDC immunization, wt mice and MyD88ko mice develop autoimmune 
myocarditis of the same severity and prevalence (Figure 10) (105). This 
characteristic phenotype allows us to further assess the role of MyD88 in the 
progression from autoimmune myocarditis to heart failure. In the model of bmDC 
induced autoimmune myocarditis, inflammation peaks at day 5 – 10 after 
immunization and starts to resolve at day 12. After resolution of inflammatory 
infiltrates in the heart, BALB/c mice develop heart failure (45). 
 
Figure 10: wt bmDC immunization induces comparable myocarditis 
severity in wt and MyD88ko mice 
Myocarditis severity scores of individual wt and MyD88ko mice, immunized with MyHC-alpha 
loaded LPS/aCD40 activated wt bmDCs at day 0 and 2. Day 10 after immunization, hearts were 
removed and examined for myocarditis severity. MyD88ko and wt mice developed myocarditis of 
the same severity and prevalence. 
 
Proinflammatory cytokine expression in the heart during autoimmune 
myocarditis 
Cardiac remodelling is a very complex mechanism that occurs in different cardiac 
diseases including myocardial infarction and heart failure (79, 80). 
Important parameters that contribute to the development of heart failure are 
proinflammatory cytokines. Among the cytokines described to be important in the 
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remodelling process are IL-1beta, IL-6 and TNF-alpha. Interestingly, all these 
cytokines have also been described to be essential for the induction of 
autoimmune myocarditis (1, 4, 5, 105). We therefore decided to measure 
proinflammatory cytokine levels in the heart at the peak of inflammation. Early 
differences in cytokine expression in the heart are likely to influence further 
development of heart failure (6). 
Wild-type and MyD88ko mice were immunized with MyHC-alpha loaded 
LPS/aCD40 activated bmDCs at day 0 and day 2. Hearts were removed at day 
10 after first immunization and mRNA was isolated. IL-1beta, TNF-alpha, IL-6 
and IL-18 cytokine expression was analyzed by RT-PCR and expression was 
normalized to beta-Actin (Figure 11). We found significantly higher levels of IL-
1beta expression in wt immunized mice when compared to MyD88ko immunized 
mice or wt control mice. There is a trend of elevated IL-6 and TNF-alpha 
expression in immunized wt mice, but this it is not statistically significant. 
 
Figure 11: cardiac expression of IL-1beta, IL-6, TNF-alpha and IL-18 after 
bmDC immunization in wt and MyD88ko mice 
RT-PCRs detecting IL-1beta, IL-6, TNF-alpha and IL-18 from heart mRNA. Wild-type and 
MyD88ko hearts were compared 10 days after bmDC immunization with healthy control hearts. A 
statistically significant increase of IL-1beta in wt immunized hearts could be detected. There is a 
trend of elevated IL-6 and TNF-alpha expression in immunized wt mice when compared to 
immunized MyD88ko mice and healthy control hearts, but not statistically significant. IL-18 
expression was expressed at low levels only in all three groups. 
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MyD88 deficiency protects from progression of proinflammatory heart 
failure 
To assess the development of heart function after autoimmune myocarditis we 
performed echocardiographic heart function measurements following post 
myocardial inflammation. 
Heart function was measured using echocardiography of the left ventricle (Figure 
12). Heart function is represented by two parameters named fractional shortening 
(FS) and velocity of circumferential fibre shortening (Vcf). Both parameters are 
derived from differences between end-diastolic left-ventricular diameter (EDD) 
and end-systolic left-ventricular diameter (ESD).  
FS and Vcf were measured 120 days after bmDC immunization in wt and 
MyD88ko mice and compared to age matched untreated wt and MyD88ko control 
mice. As a consequence of autoimmune myocarditis, wild-type mice developed 
heart failure and showed reduced FS and Vcf compared to age matched control 
mice. Interestingly, MyD88ko mice are protected from heart failure development 
after autoimmune myocarditis (Figure 13A and 13B).  
 
 
 
Figure 12: Echocardiographic analysis of heart function in mice before and 
after wt bmDC immunization in wt mice 
Exemplified pictures from echocardiographic heart function analysis before (left panel) and after 
bmDC immunization (right panel) in wt mice. Abbreviations: EDD: end-diastolic left-ventricular 
diameter; ESD: end-systolic left-ventricular diameter; IVS: intra-ventricular septum - PW: left-
ventricular posterior wall. 
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Figure 13: MyD88ko mice are protected from heart failure after autoimmune 
myocarditis 
A) Analysis of fractional shortening (FS) 120 days after immunization in wt (dark grey bars) and 
MyD88ko (light grey bars) mice compared to untreated age-matched wt (black bars) and 
MyD88ko (white bars) control mice. MyD88ko immunized mice show a statistically significant 
increase of FS when compared to wt immunized mice. 
B) Analysis of velocity of circumferential fiber shortening (Vcf) 120 days after immunization in wt 
and MyD88ko mice when compared to untreated age-matched wt and MyD88ko control mice. 
MyD88ko immunized mice show a statistically significant increase of Vcf when compared to wt 
immunized mice. 
C) Analysis of FS in wt (filled squares) and MyD88ko (open circles) mice before and 120 days 
after wt bmDC immunization. No difference in FS was observed at day 0 before immunization 
between wt and MyD88ko mice. However, at day 120 after immunization, MyD88ko immunized 
mice show a statistically significant increased FS when compared to wt immunized mice. 
D) Analysis of Vcf in wt and MyD88ko mice before and 120 days after wt bmDC immunization. No 
difference in Vcf was observed at day 0 before immunization between wt and MyD88ko mice. 
However, at day 120 after immunization, MyD88ko immunized mice show a statistically significant 
increased Vcf when compared to wt immunized mice. * p<0.01 
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To further exclude pre-existing intrinsic differences in heart function between wt 
and MyD88ko hearts, we measured heart function in wt and MyD88ko mice 
before and after bmDC immunization. At day 0, before immunization, wt and 
MyD88ko mice showed comparable heart function. We can therefore exclude 
intrinsic differences in heart function between wt and MyD88 mice. At day 120 
after bmDC immunization, wt mice show reduced heart function when compared 
to MyD88ko mice (Figure 13C and 13D).  
 
No differences in heart weight / body weight ratio or cardiomyocyte 
diameter between wt and MyD88ko mice after bmDC immunization 
Heart failure is amongst others characterized by increased heart weight to body 
weight ratio (HW/BW) and increased diameter of cardiomyocytes that describes 
a dilated, hypertrophic and functionally impaired status of the heart. To further 
describe the protection of MyD88ko mice from heart failure we measured 
HW/BW ratio and cardiomyocytes diameter 120 days after bmDC immunization. 
To our surprise, the HW/BW ratio and cardiomyocyte diameter measurements do 
not reflect the differences observed between wt and MyD88 heart functions in 
echocardiographical measurements. There was no significant difference in 
HW/BW ratio or cardiomyocytes diameter between wt and MyD88ko mice (Figure 
14A-C). 
 
Autoantibodies and T-cell response in late stage myocarditis 
In human myocarditis patients, autoantibodies against the heart are a key 
characteristic for an ongoing autoimmune response (34). We therefore measured 
autoantibodies against cardiac myosin 120 days after bmDC immunization in wt 
and MyD88ko mice. Only 2 out of 10 wt and 1 out of 10 MyD88ko mice showed 
high titers of IgG-total autoantibodies against myosin, most wt and MyD88ko 
mice show only low-level antibodies against the heart. Altogether, there is no 
significant difference in heart specific autoantibody response in the tested groups 
of 10 wt and 10 MyD88ko mice (Figure 15A and 15B). These results indicate that 
there is no pronounced ongoing humoral immune response against the heart 120 
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Figure 14: No differences in cardiomyocytes diameter or heart weight / 
body weight ratio between wt and MyD88ko mice after bmDC immunization 
A) Representative picture from Collagen IV immunohistochemistry heart staining. wt and 
MyD88ko mice were immunized with MyHC-alpha loaded LPS/aCD40 activated wt bmDCs at day 
0 and 2. 120 days after immunization, hearts were removed and stained for Collagen IV. 
B) Hearts were analyzed for cardiomyocytes diameter: 10 pictures from Collagen IV 
immunohistochemistry were taken per heart and analyzed with “analySIS Image Processing” 
software for cardiomyocyte diameter. No significant difference was observed in cardiomyocyte 
diameter between wt and MyD88ko mice. 
C) Heart weight / body weight (HW/BS) ratio was assessed 120 days after wt bmDC 
immunization in wt and MyD88ko mice. No difference was observed in HW/BW ration between wt 
and MyD88ko mice 120 days after bmDC immunization. 
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 days after immunization. To further characterize ongoing T-cell immune 
response in wt and MyD88ko mice at different time points after bmDC 
immunization, we measured whole splenocytes proliferation response against 
MyHC-alpha peptide at day 10, 20 and 120 after bmDC immunization. Positive 
proliferation response was detected in both wt and MyD88ko mice at all 
measured time points (Figure 15C-E). We therefore conclude that the Myd88ko 
mice have comparable humoral and cellular immune response to MyHC-alpha 
peptide when immunized with wt bmDCs. These findings suggest that differences 
in the ongoing T-cell and B-cell response are not responsible for observed 
differences in heart function of MyD88 and wt mice. 
 
Figure 15: Humoral and cellular immune response characterization in wt 
and MyD88ko after bmDC immunization 
A) Comparable humoral IgG-total response in wt (filled squares) and MyD88 (open circles) mice 
after bmDC immunization. Serum was collected 120 days after bmDC immunization from wt and 
MyD88ko mice and assessed for anti-myosin IgG-total antibodies. 
B) Trend to increased IgG-1 subclass response in wt mice when compared to MyD88ko mice 
after bmDC immunization. Serum was collected 120 days after bmDC immunization from wt and 
MyD88ko mice and assessed for anti-myosin IgG-1 antibodies. 
C - E) Whole splenocytes MyHC-alpha peptide restimulation in vitro from wt and MyD88ko mice 
day 10, day 20 and day 120 after bmDC immunization. Curves shown represent individual mice. 
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bmDC/CFA double immunization in wt and MyD88ko mice 
Due to the time-consuming experiments of heart failure development, we recently 
created an immunization method combining bmDC and CFA immunization, 
called “double immunization”, where wild-type BALB/c mice develop severe 
myocarditis, strong fibrosis and heart dilation at day 30 after first immunization. In 
general, the double immunization dramatically shortens the experiment length 
and leads to a more pronounced heart failure phenotype when compared to 
bmDC immunization only. This shorter length of the experiment will allow us 
investigate the interplay between autoimmune inflammation and fibrosis that lead 
to the development of heart failure more efficiently.  
We therefore decided to evaluate the myocarditis and fibrosis development in 
MyD88ko mice as a consequence of the novel bmDC/CFA double immunization 
protocol. We found that MyD88ko mice developed similar myocarditis severity at 
day 30 after first immunization when compared to wt mice (Figure 16A-D and 
16I). These data support our previous findings that MyD88ko mice have similar 
myocarditis prevalence and severity day 10 after bmDC immunization (Figure 10) 
(105). However, when assessed for fibrosis development by CAB staining, 
MyD88ko mice showed significantly reduced fibrosis in the heart when compared 
to wt mice (Figure 16E-H and 16J). Also in the measured HW/BW ratio assessed 
at day 30 after first immunization, wt mice have increased HW/BW ratio when 
compared to MyD88ko mice, implying an impaired heart function and advanced 
progression of heart failure. 
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Figure 16A-D 
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Figure 16E-H 
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Figure 16: bmDC/CFA double immunization in wt and MyD88ko mice 
wt and MyD88ko mice were immunized with MyHC-alpha loaded LPS/aCD40 activated bmDCs at 
day 0 and 2, followed by additional immunization with MyHC-CFA at day 10 and 17. Mice were 
sacrificed at day 30 and assessed for leukocyte infiltration by HE staining, Collagen deposition by 
CAB staining and heart weight-body weight ratio.  
A and B) representative pictures from three individual HE-stained wt heart sections, 25x or 400x 
magnifications depticted. 
C and D) representative pictures from three individual HE-stained MyD88ko heart sections, 25x 
or 400x magnifications depicted. 
MyD88ko mice show decreased fibrosis at day 30 after first immunization (E-H and J). 
E and F) representative pictures from three individual CAB-stained wt heart sections, 25x or 400x 
magnifications depicted. 
G and H) representative pictures from three individual CAB-stained wt heart sections, 25x or 400x 
magnifications depicted. 
I) wt and MyD88ko mice were assessed for myocarditis severity 30 days after bmDC/CFA double 
immunization. No significant differences in myocarditis severity observed. 
J) wt and MyD88ko mice were assessed for fibrosis severity 30 days after bmDC/CFA double 
immunization. MyD88ko mice show significant decreased fibrosis when compared to wt mice. 
K) MyD88 show decreased HW/BW ratio when compared to wt mice. HW/BW ratio was assessed 
30 days after first immunization 
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Discussion 
In the past few years it became apparent that Toll-like Receptor signalling may 
be involved in the development of heart failure (12). The “innate danger” model 
describes the induction of proinflammatory mediators in the heart due to TLR 
signalling. It is suggested that the heart possesses a germ-line encoded innate 
stress response. Ligands for TLRs in the heart without present infection might be 
derived from tissue injury including oxidative stress, stretch, 
ischemia/reperfusion, and neurohormonal activation (Figure 17) (12). In the 
present study we contribute to the ongoing debate about the role of TLR 
signalling in heart failure development (80). In previous studies we could show 
that mice deficient for the TLR adapter molecule MyD88 are protected from EAM 
when immunized with MyHC-CFA. However, when directly immunized with 
MyHC-loaded bmDCs, MyD88ko mice develop EAM with comparable prevalence 
and severity as wt mice (105).  
We here show, for the first time, that mice deficient for MyD88 are protected from 
heart failure development after initial autoimmune myocarditis. In functional 
assessment of heart function via echocardiography, MyD88ko mice show 
increased heart function after initial autoimmune myocarditis when compared to 
wt mice. To address the mechanisms underlying the protection in MyD88ko mice, 
we analyzed the immune response against the heart at different time points after 
bmDC immunization. We describe that MyD88ko and wt mice have comparable 
autoaggressive cellular and humoral immune response against the heart after 
MyHC-loaded bmDC immunization. These findings suggest that the ongoing 
chronic immune response might not be responsible for the observed differences 
in heart function and development of heart failure. On the other hand, despite the 
comparable T-cell proliferation response, further investigations about the TH-
phenotype in late autoimmune myocarditis and heart failure in wt and MyD88ko 
mice is necessary. It was recently shown, that the newly described TH17 
phenotype is essential for the development of autoimmune myocarditis (106, 
107). The role of IL-17 in the progression of heart failure, however, remains 
elusive. 
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Figure 17: Proposed model for innate immune responses in the heart. 
Inflammatory mediators such as tumour necrosis factor (TNF), interleukin 1 (IL-1), IL-6, and nitric 
oxide (NO) are expressed in the heart in response to “danger signals” that arise from diverse 
forms of tissue injury, including oxidative stress, stretch, ischemia/reperfusion, and 
neurohormonal activation. In addition, molecules released by stressed cells (e.g., heat shock 
protein 60 (HSP60) and fibronectin) are capable of eliciting inflammatory responses by binding to 
Toll-like receptor 4 (TLR4). Once expressed, the inflammatory mediators can exert direct effects 
on target cells by binding to their cognate receptors, or they can activate components of the 
adaptive immune system through antigen presentation or through upregulation of cell adhesion 
molecules (CAM) that attract neutrophils and monocytes. Adapted from (12) 
 
Therefore, it cannot completely be ruled out that memory immune responses 
contribute to the development of heart failure. More detailed investigations on 
memory immune responses during heart failure development are necessary. For 
example, TLR signalling has been described to be essential for the generation of 
CD4+ T-cell memory, but not for the activation of memory CD4+ T-cells (108). In 
contrast, memory B-cell express TLRs and can be directly activated through TLR 
stimulation (109).  
We also investigated the expression of proinflammatory cytokines at the peak 
level of inflammation at day 10 after the first bmDC immunization. We 
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hypothesize according to the “cytokine hypothesis”, that the proinflammatory 
cytokine patterns expressed during acute inflammation might determine heart 
failure development. In the “cytokine hypothesis” of myocardial dysfunction, 
myocardial injury is associated with the elaboration of proinflammatory molecules 
by both immune effector cells, as well as cells intrinsic to the heart (6, 78). There 
is no single cytokine responsible for the development and progression of heart 
failure but rather a proinflammatory-cytokine cascade and their downstream 
effectors produce alterations in myocardial function. The induction of the 
proinflammatory cascade follows the production of three main cytokines, namely 
Interleukin-1, TNF-alpha and IL-6 (110). 
The pathogenic role of IL-1 and IL-1R signalling in heart failure has been 
associated with increased IL-1beta expression in hearts of patients with 
idiopathic dilated cardiomyopathy (111). In addition, Il-1beta has also direct 
ionotrop/chronotrop effects on the heart (110, 112, 113). Furthermore, IL-1beta 
has been described to modulate adhesion molecule expression which is 
essential for the recruitment of proinflammatory cells to the heart (114).  
We could show that wt mice significantly express higher amounts of IL-1beta in 
the heart during acute myocarditis. Interestingly, the IL-1 Receptor (IL-1R) uses 
the same signalling transduction pathways as the TLRs; both signal through the 
Toll/IL-1R adaptor molecule MyD88. Therefore, MyD88ko mice after autoimmune 
myocarditis induction not only have reduced IL-1 expression in the heart, but the 
remaining IL-1 levels are unnoticed due to the interrupted IL-1R signalling in 
MyD88ko mice. These findings lead to the hypothesis that IL-1R signalling plays 
an important role in the progression from autoimmune myocarditis to heart 
failure. Nevertheless, the ligands for TLR induced IL-1 expression in the heart 
remain unknown.  
We further characterized myocarditis and fibrosis development in wt and 
MyD88ko mice with a novel immunization protocol combining bmDC- and CFA-
immunization. This protocol leads to strong fibrosis development and dilation of 
wt hearts already at day 30 after first immunization. We describe that MyD88ko 
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mice have reduced cardiac fibrosis and improved HW/BW ratio when compared 
to wt mice.  
In summary we could show that after initial autoimmune myocarditis, MyD88ko 
mice are protected from heart failure with increased heart function, reduced IL-
1beta expression and reduced cardiac fibrosis. Our data strongly supports the 
theory that TLR signalling is involved in the development of heart failure. We 
believe that better understanding of TLR signalling pathways in the heart 
including the identification of endogenous TLR ligands may contribute to novel 
treatment strategies against autoimmune induced heart failure. 
   63 
  
 
 
 
 
THE ROLE OF TYPE I INTERFERON RECEPTOR SIGNALLING IN 
EXPERIMENTAL AUTOIMMUNE MYOCARDITIS INDUCTION 
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Introduction 
It is well-established that viral infections can cause autoimmunity (115). Diseases 
associated with viral induced autoimmunity are, amongst others, diabetes type I, 
myocarditis, thyroiditis and multiple sclerosis (20, 116, 117). However, the 
precise mechanisms of disease induction are not yet resolved (36, 118, 119).  
The initiation of any host immune response against viral infections strongly 
depends on the expression of type I IFN (84). Type I IFN expression is initiated 
through pathogen interaction with toll-like receptors (TLR). Signal transduction 
mainly occurs via TLR3, TLR7, TLR8 and TLR9 signalling pathways (Figure 18) 
but TLR independent mechanisms can also lead to type I IFN expression (120). 
The type I IFN family consists of multiple members (α, β, ε, δ, κ, τ, ω and limitin), 
which are expressed by a variety of cell types and exert multiple 
immunomodulatory effects including stimulation of polyclonal T-cell responses, 
isotype switching, expression of class I major histocompatibility complex (MHC) 
molecules, and induction of dendritic cell differentiation (17, 121). 
So far, there has been extensive research on the effect of type I IFN against viral 
infections in the heart (16, 23, 122-124). Kühl et al. showed in a phase II cohort 
study, that IFN-beta can be used to treat patients suffering from dilated 
cardiomyopathy with the presence of viral genomes in the heart (24). IFN-beta 
therapy has been shown to increase left ventricular function and to eliminate viral 
genomes in the heart (24). However, the role of type I IFN on the autoimmune 
properties of chronic myocarditis has not yet been investigated.  
Type I IFN levels have been correlated with clinical manifestations of Systemic 
Lupus Erythematosus (SLE) (18) and Sjogren's syndrome (19). On the other 
hand, administration of IFN-beta1 has been shown to prevent progression of 
multiple sclerosis (125). In a recent publication addressing the role of TLRs in a 
transgenic mouse model of CD8+ T-cell mediated autoimmune diabetes mellitus, 
it was shown that TLR activation induces IFN-alpha expression that further 
upregulates class I MHC expression initiating pancreas destruction (70). This 
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example highlights the importance of TLR induced type I IFN as 
immunomodulatory agents in the pathogenesis of autoimmune diseases.  
For my thesis I am specifically interested in the role of the innate immune system 
in EAM development. In this context we further addressed the role of type I IFN 
signalling during EAM induction. Regarding the above-mentioned role of type I 
IFN in other inflammatory diseases, type I IFN signalling could both, protect from 
autoimmune myocarditis as well as aggravate the disease. In the context of 
human myocarditis, our research aims to contribute to the ongoing debate 
whether or not to treat chronic myocarditis patients with type I IFN. 
To assess the role of type I IFN in the development of autoimmune heart 
disease, we examined the myocarditis susceptibility of mice that genetically lack 
the IFN type I receptor (IFNαβRko) (84). The multiple IFN-alpha/beta members 
share a ubiquitously expressed heterodimeric receptor composed of IFN-alpha-
receptor subunit 1 (IFNAR1) and IFNAR2. Both receptor chains are required for 
signal transduction (121). The IFNαβRko mice genetically lack the IFNAR1 
subunit and are therefore completely unresponsive to IFN-alpha and IFN-beta. 
Here we describe for the first time that type I IFN signalling is critical in inducing 
heart-specific autoimmunity in the presence of autoreactive T-cell responses.  
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Figure 18:  
TLRs engaged in IFN-alpha-beta production. Endogenous ligands, such as apoptotic/necrotic 
material and nucleoproteins complexed with autoantibodies, and exogenous ligands, such as 
bacterial lipopolysaccharide (LPS), bacterial hypomethylated CpG-DNA, and viral ssRNA or 
dsRNA, bind to the indicated TLRs on cell surfaces or in endosomal compartments. TLR 
signalling phosphorylates IRF-3 and initiates IFN-beta transcription. Subsequent signalling 
through IFNαβR leads to IRF-7 and IFN-alpha expression. Adapted from (17) 
   67 
Results 
IFN-beta expression is upregulated in hearts with myocarditis  
In a first experiment we induced autoimmune myocarditis in wt BALB/c mice 
using the dendritic cell immunization protocol (45). Dendritic cell immunization 
has certain advantages over the classical MyHC-CFA immunization (41). 
Dendritic cell immunization directly administers heart-specific peptide loaded 
antigen presenting cells that induce an organ specific autoimmune response 
against the heart without systemic inflammation or confounding TLR stimulation. 
It is therefore possible to measure changes in cytokine expression in the heart as 
a direct consequence of the autoimmune myocarditis response that is not 
falsified by a general inflammatory response to the Mycobacterium tuberculosis 
H37Ra present in the CFA. 
We then measured IFN-alpha and IFN-beta expression in myocarditis hearts 9 
days after wt MyHC-bmDC immunization. IFN-alpha expression could not be 
detected (not shown). IFN-beta expression is upregulated in five out of seven 
hearts from bmDC immunized wt mice compared to wt control hearts (Figure 19).  
 
Interferon-alpha-beta receptor signalling is crucial for autoimmune 
myocarditis induction 
To specifically address the role of type I IFN signalling in autoimmune 
myocarditis induction, we decided to assess the myocarditis phenotype in 
IFNαβRko mice. These mice do not express the IFN type I receptor and are 
therefore unresponsive to IFN-alpha as well as IFN-beta. To our surprise, we 
found that IFNαβRko mice are completely protected from wt bmDC immunization 
(Figure 20A & 20C). In the same experiment we further demonstrated that 
IFNαβRko splenocytes have a reduced in vitro proliferation response against 
MyHC-alpha peptide 10 days after bmDC immunization (Figure 20B).  
In the model of bmDC induced autoimmune myocarditis in wt BALB/c mice, 
inflammation peaks at day 5 – 10 after immunization and starts to resolve at day  
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Figure 19: IFN-beta mRNA expression is upregulated in hearts with 
myocarditis 
Myocarditis was induced by injecting MyHC-alpha loaded, LPS/aCD40 activated bmDCs at day 0 
and 2. Hearts from immunized mice were isolated at day 9 and mRNA was extracted from 
immunized hearts (filled diamonds) as well as from naïve control hearts (open circles). IFN-beta 
expression was detected by RT-PCR. Myocarditis hearts express elevated levels of IFN-beta 
compared to healthy control hearts. IFN-beta expression levels were standardized against beta-
Actin expression. 
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Figure 20: Protection from myocarditis in IFNαβRko mice after bmDC 
immunization 
Myocarditis was induced by injecting MyHC-alpha loaded and LPS/aCD40 activated bmDCs at 
day 0 and 2. Wild-type bmDCs were injected into wild-type mice (filled squares) or in IFNαβRko 
mice (open circles). 
A) After 10 days, hearts were scored histologically for inflammation. IFNαβRko mice were 
protected from bmDC induced myocarditis. 
B) In the same experiment, spleens were removed and splenocytes were restimulated in vitro 
with MyHC-alpha at different concentrations and proliferation was assessed by 3H-Thymidine 
incorporation. IFNαβRko splenocytes showed reduced in vitro proliferation response against 
MyHC-alpha peptide 10 days after bmDC immunization when compared to wt mice. 
C) Representative images of Hematoxilin & Eosin staining of wild-type and IFNαβRko heart 
sections. Original magnification 15x and 400x. 
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12 (45). Due to the reduced in vitro response of IFNαβRko splenocytes against 
MyHC-alpha peptide as shown in Figure 20B, we addressed the hypothesis that 
IFNαβRko mice might show delayed myocarditis development after wt bmDC 
immunization. We therefore tested myocarditis susceptibility of IFNαβRko mice 
15 days after the first bmDC immunization. At day 15 post bmDC immunization, 
nine out of twelve IFNαβRko mice were completely protected from experimental 
autoimmune myocarditis (Figure 21A) and only two mice showed grade 1 
myocarditis. We conclude that IFNαβRko mice are protected from bmDC induced 
myocarditis at every measured time point. 
 
Interferon Type I Receptor deficient bmDCs induce myocarditis in wt mice 
IFN type I signalling might influence priming of autoreactive T-cells not only on 
the level of T-cells but may also influence the antigen presenting cells directly. 
IFNαβR signalling modulates co-stimulation, cytokine secretion as well as 
migration and survival of dendritic cells in vivo (17, 126). To further address the 
role of type I IFN signalling on bmDCs during myocarditis induction we analyzed 
CD40, 80, 86 and IA-d surface molecules expression and TNF-alpha and IL-
12p70 intracellular expression in IFNαβRko and wt bmDCs after in vitro LPS 
activation (Figure 21C-H). No major differences were found in surface molecule 
expression or cytokine production in INFabRko bmDCs compared to wt bmDCs. 
We then immunized wt mice with MyHC-alpha loaded IFNαβRko-bmDCs (Figure 
21B). One out of five mice developed medium range myocarditis and three mice 
developed minimal myocarditis indicating that IFNαβRko bmDCs are able to 
induce autoimmune myocarditis although presumably at lower levels. 
 
bmDC migration in wt and IFNαβRko mice 
To further assess the mechanisms of protection in IFNαβRko mice after wt 
bmDC immunization, we tested bmDC migration capacity in wt and IFNαβRko 
mice. The reduction in T-cell priming in IFNαβRko mice could be explained by 
impaired migration of bmDCs in IFNαβRko mice to the site of T-cell priming. Our 
routine immunization pathway for bmDC immunization is intra-peritoneal  
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Figure 21:  
A) Myocarditis score at late time point day 15 after bmDC immunization in wt and IFNαβRko 
mice. No significant differences observed between wt and IFNαβRko mice. 
B) wt BALB/c mice were immunized at day 0 and 2 with 0.5 Mio MyHC-alpha loaded LPS/aCD40 
activated IFNαβRko bmDC. Day 10 after first immunization, myocarditis severity was assessed. 
One out of five mice developed medium range myocarditis and three mice developed minimal 
myocarditis indicating that IFNαβRko bmDCs are able to induce autoimmune myocarditis 
although presumably at lower levels 
C-H: FACS analysis of CD11positive in vitro generated bmDC before and after 4h LPS activation. 
Filled grey curve represents wt naïve bmDCs; black solid line represents LPS activated wt 
bmDCs; red solid line represents LPS activated IFNαβRko bmDCs. 
C) Histogram of CD80 surface expression analysis on CD11c positive bmDCs 
D) Histogram of CD40 surface expression analysis on CD11c positive bmDCs 
E) Histogram of IL-12 p70 intracellular expression analysis on CD11c positive bmDCs 
F) Histogram of CD86 surface expression analysis on CD11c positive bmDCs 
G) Histogram of AI-d-MHC II surface expression analysis on CD11c positive bmDCs 
H) Histogram of TNF-alpha intracellular expression analysis on CD11c positive bmDCs 
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injection. We know from previous experiments that bmDC migrate to the 
mesenteric lymph nodes and the spleen but not to the heart (45). Further 
experiments showed that the spleen is not necessary for autoimmune 
myocarditis development after bmDC immunization. Splenectomized wt BALB/c 
mice develop myocarditis after bmDC immunization (Figure 22A).  
For migration assessment we transferred CFSE labelled wt CD11c positive 
bmDCs in wt and IFNαβRko mice intraperitoneal. Two days after transfer, we 
measured CFSE-positive CD11c-positive bmDCs in mesenteric lymph nodes 
(Figure 22B). Although reduced, there are comparable numbers of CFSE positive 
DCs in the lymph nodes of IFNαβRko mice and wt mice. Since priming of MyHC-
specific T-cells in IFNαβRko mice is present but reduced and the fact that CFSE 
positive bmDCs migrate to mesenteric lymph nodes in IFNαβRko mice, we 
conclude that migration of bmDCs most likely is not the principle mechanism of 
protection in IFNαβRko mice. However, further experiments are required to 
address bmDC migration in IFNαβRko and wt mice in more detail. 
 
Figure 22: bmDC migration in wt and IFNαβRko mice  
A) Splenectomyzed BALB/c mice develop myocarditis after bmDC immunization with slightly 
reduced severity and prevalence compared to control BALB/c mice after bmDC immunization. At 
day 10 and 12 after splenectomy, mice were immunized with MyHC-alpha loaded, LPS/aCD40 
activated bmDCs and sacrificed at day 10 after first bmDC immunization. 
B) Mesenteric lymph nodes were isolated 2 days after i.p. injection of CFSE labelled bmDCs. 
bmDC migration into mesenteric lymph nodes was analyzed by flowcytometry detecting CFSE 
and CD11c double positive bmDCs. IFNαβRko mice show slightly reduced migration of CFSE 
positive DCs to the mesenteric lymph nodes of IFNαβRko mice when compared to wt mice. 
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IFNαβRko mice are protected from autoimmune myocarditis after MyHC-
alpha specific CD4+ T-cell transfer 
The IFN type I receptor is expressed in various cell types including APCs, B- and 
T-cells. Different members of the type I IFN family have pleiotropic effects on the 
induction and maintenance of immune response and are therefore key players in 
immune regulation (121). As shown in Figure 20B, IFNαβRko mice show reduced 
immune response to MyHC-alpha peptide after wt bmDC immunization. We 
further wished to assess whether expansion or migration mechanisms of 
autoreactive T-cells plays a role in myocarditis protection in IFNαβRko mice. We 
therefore generated a MyHC-alpha specific wt CD4+ T-cell line. Adaptive transfer 
of MyHC-alpha specific wt CD4+ T-cells circumvents in vivo priming and therefore 
we directly assessed the role of T-cell expansion and migration in vivo. The 
generated wt CD4+ T-cells specific for MyHC-alpha peptide show high IFN-
gamma (not shown) and intermediate IL-17 cytokine secretion levels (Figure 
23A).  
After adoptive transfer of heart specific T-cells, IFNαβRko mice were protected 
from autoimmune myocarditis (Figure 23B and 23C). Nevertheless, wt CD4+ 
MyHC-specific T-cells could still be found in spleens of IFNαβRko mice after 
adoptive transfer. We isolated spleens 10 days after adoptive transfer and 
restimulated whole splenocytes in vitro with MyHC-alpha peptide. Both wt and 
IFNαβRko splenocytes responded to MyHC-alpha peptide, albeit with slightly 
different proliferation patterns depending on peptide concentration (Figure 23D). 
Reduced proliferation of heart-specific T-cells in IFNαβRko mice after adoptive 
transfer might indicate that the conditions for expansion of heart specific T-cells 
in secondary lymphoid organs in IFNαβRko mice are less favourable than in wt 
mice. This could indicate that APCs in the IFN receptor type I deficient mouse 
are less efficient in activating and expanding MyHC-alpha specific CD4+ T-cell 
than wt APCs. However, protection of IFNαβRko mice from myocarditis could 
also arise from impaired recruitment of CD4+ T-cells to the heart or impaired 
recruitment of inflammatory infiltrates to the heart. 
   74 
These findings indicate that the IFNαβRko mice do not only have reduced 
adaptive immune response against MyHC-alpha peptide as shown in Figure 20C, 
but might also have further mechanisms that prevent autoimmune myocarditis.  
 
Figure 23: IFNαβRko mice are protected from myocarditis after MyHC-alpha 
specific adoptive wt T-cell transfer 
A) FACS analysis of MyHC-alpha specific wt T-cells expressing intermediate amounts of IL-17. 
B) 10 days after adoptive transfer, inflammation in hearts was scored by histology. IFNαβRko 
mice are completely protected from myocarditis after adoptive MyHC-alpha specific wt T-cell 
transfer. 
C) Representative images of Hematoxilin & Eosin staining of wt and IFNαβRko heart sections. 
Original magnification 400x. Left figure panel: arrows pointing on cardiomyocytes (red) 
surrounded by infiltrating lymphocytes. 
D) In the same experiment, spleens were removed and whole splenocytes were restimulated with 
different concentrations of MyHC-alpha peptide and proliferation was assessed by 3H-Thymidine 
incorporation. Each group represents a pool of two mice. Both wt and IFNαβRko mice respond to 
MyHC-alpha peptide, albeit with slightly different proliferation patterns depending on peptide 
concentration. 
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MyHC-alpha specific IFNαβR deficient CD4+ T-cells transfer myocarditis in 
wt mice 
To further investigate the protection mechanisms in IFNαβRko mice we 
addressed the potential of heart specific IFNαβRko T-cells in inducing 
myocarditis in wt mice.  
If heart-specific IFNαβRko T-cells have intrinsic defects due to their inability to 
signal IFN type I cytokines, they would therefore fail to transfer myocarditis. On 
the other hand, if the protection mechanism in IFNαβRko mice after bmDC 
immunization is based on altered migration patterns of T-cells, then IFNαβRko 
MyHC-alpha specific T-cells should be able to induce myocarditis in wt mice. To 
address this hypothesis, we generated a MyHC-alpha specific IFNαβRko CD4+ 
T-cell line (Figure 24A). After adoptive transfer of IFNαβRko T-cells, wt mice 
develop myocarditis (Figure 24B). Therefore we conclude, that IFNαβRko 
signalling is not essential in T-cells for the induction of autoimmune myocarditis. 
The protection mechanisms in IFNαβRko mice are more likely to be dependent 
on reduced expansion and impaired migration of MyHC-alpha specific T-cells 
from the secondary lymphoid tissue to the heart. Moreover, impaired recruitment 
of leukocytes to the heart would also be a possible mechanism of protection. 
 
Figure 24: IFNαβRko MyHC-alpha specific T-cells induce myocarditis in wt 
mice 
A) FACS analysis of wt and IFNαβRko MyHC-alpha specific CD4+ T-cells expressing IL-17.  
B) 10 days after adoptive transfer of MyHC-specific wt or IFNαβRko T-cells into wt BALB/c mice, 
inflammation in hearts was scored by histology. MyHC-specific IFNαβRko T-cells induced 
myocarditis in BALB/c mice with the same prevalence and severity as MyHC-specific wt T-cells. 
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bmDC induced myocarditis in chimeric wt and IFNαβRko mice 
So far, we showed that MyHC-alpha specific IFNαβRko T-cells transfer 
myocarditis in wt mice but MyHC-alpha specific wt T-cells fail to transfer disease 
in IFNαβRko mice. It would hence be of interest to address the role of IFNαβR 
signalling in the vasculature and the heart for its function in the recruitment of 
leukocytes to the heart during autoimmune myocarditis induction after wt bmDC 
immunization. To better understand the importance of IFNαβRko signalling in the 
recruitment of autoreactive T-cells to the heart, we generated chimeric mice with 
either wt bone marrow in IFNαβRko mice or vice versa. 
6 weeks after the generation of chimeras, we immunized them with wt bmDC. 
Myocarditis developed in both groups, however disease severity was low and no 
significant differences were observed between the two chimera groups at this 
time point after disease induction (Figure 25). 
 
 
Figure 25: Myocarditis in wt and IFNαβRko bone marrow chimeras 
Chimeric mice were generated with either wt bone marrow in IFNαβRko mice or vice versa. 
Myocarditis was induced by injecting MyHC-alpha loaded and LPS/aCD40 activated bmDCs at 
day 0 and 2. Wild type bmDCs were injected in wild type mice with IFNαβRko bone marrow (filled 
diamonds) or in IFNαβRko mice with wt bone marrow (open circles). After 10 days, hearts were 
scored histologically for inflammation. No significant difference was observed. 
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Discussion 
In this study we examined the role of type I IFN receptor signalling in the 
development of autoimmune myocarditis. We could show for the first time that 
IFN-beta expression is upregulated in the heart during autoimmune myocarditis. 
Furthermore, taking advantage of the IFN type I receptor deficient mice, we 
report that IFNαβR deficiency results in decreased autoimmune myocarditis. We 
showed that myocarditis incidence and severity was reduced in both bmDC-
induced myocarditis as well as after adoptive transfer of MyHC-specific CD4+ T-
cells. Consistent with this observation was the reduced priming capacity of 
autoreactive CD4+ T-cells after bmDC immunization in IFNαβR deficient mice. 
However, at the level of T-cells, in vitro expanded IFNαβR deficient MyHC-
specific T-cells transfer myocarditis into wt mice. We therefore conclude that 
IFNαβR signalling at the level of T-cells is not required for T-cell infiltration in the 
heart and for the induction of autoimmune myocarditis. These findings lead to the 
question as to why IFNαβRko mice show reduced autoreactive T-cell priming 
when immunized with fully matured and activated wt bmDCs? And how does 
IFNαβRko deficiency in the host influence priming of autoreactive T-cells?  
In the concept of the “adjuvant effect” (127), priming of autoreactive T-cell 
requires two preconditions. First, auto-antigen has to be released due to tissue 
damage or imitated by molecular mimicry of infectious agents. Second, infections 
acting as adjuvants induce an inflammatory milieu that favours priming of 
autoreactive T-cells and the development of autoimmunity (Figure 26). Noel R. 
Rose suggests that the inflammatory environment itself is important for the 
priming of autoreactive T-cells (127). We therefore hypothesize that type I IFN 
might be an important player in the induction of an inflammatory environment 
favouring priming of autoreactive T-cells.  
In order to prime efficient T-cell responses, antigen-presenting cells, especially 
dendritic cells, need to be in an activated maturation status expressing high 
levels of MHC class I & II molecules, costimulatory molecules as well as 
proinflammatory cytokines. Type I IFN is essential for the maturation process of 
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antigen presenting cells to fully exert efficient T-cell priming. Recent studies have 
demonstrated that dendritic cells both produce type I IFN and undergo 
maturation in response to type I IFN (128). We hypothesize that mice lacking 
type I IFN signalling fail to induce a proinflammatory environment that favours the 
priming of autoreactive T-cell that subsequently induces autoimmunity. However, 
we could show that IFNαβRko bmDCs are able to induce myocarditis in wt mice. 
We therefore can exclude feedback mechanisms acting on the injected bmDCs. 
Therefore, the cell-types and signals contributing to an inflammatory milieu that 
enables efficient priming between wt bmDCs and IFNαβRko T-cells remain 
obscure.  
The suggested “adjuvant effect” has similar characteristics as the described 
“bystander activation” of CD4+ and CD8+ T-cell during viral infection or innate 
activation (129). Bystander activation describes non-specific activation and 
proliferation of CD4+ or CD8+ T-cell upon infections. Infections lead to significant 
maturation and activation of APCs such as dendritic cells. Maturation can be 
induced directly through pathogen recognition receptors on DCs, in particular 
TLRs (130). In addition, DCs can respond indirectly to cytokines, secreted from 
other cells (131). These activated APCs could potentially activate preprimed 
autoreactive T-cells, which can then initiate autoimmune disease (bystander 
activation of autoreactive immune T-cells) (132).  
 
So far we discussed the possible mechanisms that contribute to reduced priming 
of autoreactive T-cell in IFNαβRko mice. Further findings from T-cell transfer 
experiments suggest additional protection mechanisms in IFNαβRko mice. 
Adoptive transfer of MyHC-alpha specific wt T-cells directly induces autoimmune 
myocarditis in wt mice (105). In contrast to wt mice, IFNαβRko mice are 
protected from autoimmune myocarditis development after transfer of MyHC-
specific wt CD4+ T-cells. We found that MyHC-specific wt CD4+ T-cells survive in 
IFNαβRko mice and remain antigen specific upon MyHC-alpha in vitro 
restimulation. However, restimulation capacity is reduced when compared to wt 
mice. Based on these results we suggest two possible mechanisms that could 
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protect IFNαβR deficient mice from autoimmune myocarditis. First, MyHC-alpha 
specific T-cells in IFNαβRko mice might be unable to infiltrate the myocardium. 
Second, once infiltrated in the heart, MyHC-specific CD4+ T-cells might be 
unable to recruit further inflammatory cells such as DCs, macrophages or 
monocytes.  
Autoimmune myocarditis infiltrates mainly consist of CD11b positive macrophage 
like cells, dendritic cells, eosinophils, neutrophils, B-cells, granulocytes, mast-
cells as well as CD4+ and CD8+ T-cells (42). In the concept of disease induction, 
we believe that first, CD4+ T-cells migrate to the heart and second, CD4+ T-cells 
further recruit inflammatory cells to the myocardium. This process is amongst 
others orchestrated by proinflammatory cytokines secreted from heart specific 
CD4+ T-cells that directly or indirectly induce chemokine expression and infiltrate 
recruitment (107). In one of our first experiments, we could show IFN-beta 
expression in the heart during active autoimmune myocarditis in wt mice. It is 
likely, that IFN type I receptor signalling in the heart is essential for the 
recruitment of additional infiltrating cells after the fist wave of CD4+ T-cell 
infiltration. We hypothesize that type I IFN signalling influences migration and 
infiltration of leukocytes to the heart. However, further research has to be 
performed to address this specific characteristic of IFN-beta signalling within the 
heart. 
The potential of type I IFN to modulate monocyte trafficking has been described 
in the context of other autoimmune diseases such as multiple sclerosis and its 
animal model of Experimental Autoimmune Encephalomyelitis (EAE) (133). The 
use of IFN-beta in treating MS is well known (15). Moreover, mice deficient in 
IFN-beta show augmented and chronic EAE (134). The mode of action of IFN-
beta as a therapeutic agent for multiple sclerosis has multiple manifestations. Of 
the known immunomodulatory effects of IFN-beta are amongst others the 
inhibitory effect on the production of matrix metalloproteases (135), and 
modulatory effects on the expression of adhesion molecules and chemokines 
(133, 136, 137). We therefore further investigated the role of lymphocyte 
trafficking in the protection mechanism of IFNαβRko mice when immunized with 
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bmDCs. We generated chimeric IFNαβRko mice with wt bone marrow and 
chimeric wt mice with IFNαβRko bone marrow. After immunization with bmDCs, 
both groups develop autoimmune myocarditis. However, only low-level disease 
of myocarditis developed and no significant differences can be observed. 
 
In summary, type I IFN receptor signalling affects autoimmune myocarditis 
induction on many levels. We could show that IFNαβRko mice are protected from 
disease induction, however, the precise protection mechanisms are still 
unknown. Our studies once more highlight the immunomodulatory potential of the 
type I IFN family in autoimmune diseases. Further work is required to determine 
the role of IFNαβR signalling in disease induction and progression of 
autoimmune myocarditis in more detail. For future research strategies, I believe 
that by narrowing down the IFNαβRko signalling pathway, (for example 
addressing EAM phenotype in IRF-7, or IFN-beta deficient mice), could greatly 
enhance our knowledge of type I IFN signalling in EAM. In addition, it would be of 
great interest to observe autoimmune myocarditis prevalence, severity and heart 
failure development during IFN-alpha or IFN-beta administration in wt mice.  
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Figure 26 
Microbial and viral infections result in tissue destruction, necrosis and release of cardiac 
selfantigens. In the presence of TLR stimuli – either microbial products or endogenous TLR 
ligands are released from dying cells – selfantigen presenting dendritic cells become activated in 
the draining lymphatic tissue. Excessive DC activation and release of high amounts of IL-23, IL-6, 
TNF-alpha and TGF-beta breaks peripheral tolerance and induces heart specific autoimmunity. 
Genetic predisposition and/or the presence of heart-specific T-cells from former infections with 
intruders mimicking cardiac selfantigens, both define the DC activation threshold required for the 
induction of autoimmunity. Adapted from (44) 
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GENERAL CONCLUSIONS AND DISCUSSION 
This dissertation addresses the role of the innate immune system in EAM, a 
murine model of CD4+ T-cell mediated autoimmune myocarditis. In this context I 
focussed my research on the contribution of the TLR adaptor molecule MyD88 
and the IFNαβR in disease induction. 
We showed that MyD88 dependent TLR signalling is essential for the 
development of EAM upon MyHC-CFA immunization. We demonstrated that 
MyD88 is essential for the activation of self-antigen presenting DCs to induce 
heart-specific CD4+ T-cell responses in the peripheral compartments in vivo. We 
further showed that MyD88 dependent proinflammatory cytokine secretion of 
APCs is essential for the priming of heart-specific autoreactive T-cells. Our 
findings provide a proof of concept that the lymphatic compartment of MyD88 
deficient mice is fully competent to allow the development of autoimmune CD4+ 
T-cell responses if it becomes substituted with appropriately activated self-
antigen loaded antigen presenting cells. In addition, adoptive transfer of activated 
heart-specific autoreactive CD4+ T-cells induced myocarditis in MyD88 deficient 
mice, suggesting that MyD88 signalling affects neither CD4+ T-cell recruitment 
nor accumulation of other inflammatory cells in the heart.  
Other experimental autoimmune murine disease models that use CFA as 
adjuvant confirmed our results of impaired CD4+ T-cell priming in MyD88 
deficient mice after MyHC-CFA immunization. MyD88 deficient mice are resistant 
to disease induction in Experimental Autoimmune Uveitis and Experimental 
Autoimmune Encephalomyelitis (67, 68). These studies highlight the role of 
APCs and DCs in particular as key players in the generation of autoimmune T-
cell responses. Under normal physiological conditions, the most important 
function of DCs is the generation of innate and adaptive immunity to infections 
(131, 138). DCs are specialized to process antigens, presenting them as 
peptides bound to MHC products and initiating immunity. However, there is 
increasing evidence that DCs in situ induce antigen specific unsresponsiveness 
or tolerance in the periphery. Central tolerance is efficient, but not perfect. 
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Autoreactive T-cells may escape deletion, or self antigens may be expressed 
later in life, after the lymphocyte repertoire has been formed (139, 140). 
Peripheral tolerance is therefore necessary to support central tolerance (43). 
Immature dendritic cells continually capture and present self- and harmless 
environmental antigens. Naïve T-cells are deleted after recognizing ligands on 
these immature DCs and therefore maintain self-tolerance (98, 141). The 
concept of DC induced autoimmunity therefore implies that autoimmunity 
develops if TLR activation coincides with release and uptake of selfantigen in 
lymphatic organs of genetically susceptible individuals (45). In this case, DC 
maturation and presentation of antigens has to be tightly regulated especially at 
the site of infection where DCs not only capture the pathogen but also are likely 
to be taking up dying cells. How DCs avoid the risk of inducing autoimmunity to 
self-antigens and chronic reactivity to environmental proteins is a major topic of 
current research. Steinman and Nussenzweig suggest that immature DCs induce 
antigen-specific peripheral tolerance in the steady state, before DC maturation 
during inflammation and infection (98). During infection, DCs mature in response 
to pathogen signals. Two major receptor families play important roles in the 
maturation of dendritic cells: TLRs (142, 143) and TNF-receptors including CD40 
(144, 145). This thesis therefore provides novel data that TLR induced 
maturation of DCs through the MyD88 signalling pathway is a prerequisite for the 
generation of autoimmune response and loss of peripheral tolerance. 
 
We also addressed the role of MyD88 in the induction of heart failure. Heart 
failure is a complex multi-step disorder in which a number of physiologic systems 
participate in its pathogenesis (146). Chronic myocarditis is a leading cause of 
heart failure development (20). Numerous studies have demonstrated that heart 
failure patients have raised circulating levels of inflammatory cytokines such as 
TNF-alpha, IL-1, IL-6, as well as several chemokines, such as monocyte 
chemoattractant peptide (MCP-1), IL-8, and macrophage inflammatory protein 
(MIP-1alpha) (7-11). Chronic myocarditis patients only present with clinical 
symptoms weeks to months after the initial cardiac infection. The cause of heart 
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failure development is often unknown and complicates diagnosis and affects 
treatment strategy. Novel treatment strategies to stop the onset of heart failure 
development are therefore of great clinical interest.  
Proinflammatory cytokines belong to the family of innate effector cytokines. We 
hypothesize that the innate immune system might contribute to the development 
of heart failure. Hence, we further addressed the role of MyD88 in the 
development of autoimmune myocarditis mediated heart failure. We could 
demonstrate by echocardiographic heart function assessment that MyD88 mice 
show increased heart function after autoimmune myocarditis when compared to 
wt mice. These results indicate an additional role for MyD88 and TLR signalling 
beyond immune system activation in the heart. We provide additional evidence 
that the heart possesses an innate danger program that reacts upon initial injury, 
which is involved in the development of heart failure. We hypothesize that MyD88 
dependent cytokine signalling through the IL-1 Receptor or MyD88 dependent 
production of proinflammatory cytokines in the heart upon stress reaction or 
injury contribute to the development of heart failure. On the other hand, 
proinflammatory cytokines can also have protective properties in stress related 
responses in the heart (6). It is suggested that proinflammatory cytokines can 
induce short-term protective effects as for example the protection of cardiac 
myocytes against either hypoxic or ischemic injury (147). Knuefermann argues 
that due to the phyllogenetically ancient characteristics of the innate system, the 
innate stress response in the heart was developed to protect organisms with 
short live span. Otherwise, when activated over a prolonged time-period, 
maladaptive effects may abound. Thus, activation of the innate stress response 
system was never intended to provide long-term adaptive responses to the host 
organism (12). 
During the course of assessing MyD88 induced heart failure we created a novel 
immunization protocol combining bmDC and CFA immunization. We here provide 
the first data that indicates a fast progression of fibrosis as well as dilation in 
hearts of wt BALB/c mice after double immunization. We believe that this specific 
protocol might be useful in future studies addressing innate stress responses in 
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heart failure development. So far, our research has focused on the contribution of 
MyD88 in the development of innate and adaptive immune responses against the 
heart and the induction of proinflammatory cytokine response within the heart. In 
the context of heart failure development it will be interesting to increase the area 
of investigation to further mechanisms that might contribute to disease onset. For 
example, preliminary data from Davide Germano in the Eriksson laboratory 
indicate that MyD88 might also play a role in the recruitment of bone marrow 
derived fibroblast and macrophage precursor cells in Bleomycin induced lung 
fibrosis. It will therefore be of great interest to further address the role of MyD88 
in the recruitment of bone marrow derived precursor cells to the inflamed heart 
and its contribution to the development of fibrosis and heart failure. 
 
The MyD88 independent TLR signalling pathways in EAM induction were also 
investigated. MyD88 independent signalling is mainly responsible for the 
induction of type I IFN. We therefore took advantage of IFNαβR deficient mice to 
study the role of type I IFN signalling in EAM induction. We could show that 
IFNαβR deficient mice are protected from bmDC induced autoimmune 
myocarditis. We provide evidence that the protection coincides with reduced T-
cell priming and suggest an additional role for type I IFN signalling in the 
recruitment of proinflammatory cells to the heart. We showed for the first time 
that type I IFN is involved in the induction of autoimmune responses against the 
heart. However, the exact mechanisms contributing to reduced T-cell priming 
remain elusive. One possible mechanism might be the crosstalk of IFNαβR 
signalling with other signalling pathways important for disease induction. For 
example, Mitani et al. recently reported a unique signalling crosstalk between 
IFN-alpha-beta and IL-6 signalling. It was shown that efficient IL-6 signalling 
requires constitutive subthreshold IFNαβR signalling for the activation of IL-6 
transcription factors (148). IL-6 is a critical factor for the induction of IL-17 
expressing CD4+ T-cells (149, 150). IL-17 has been shown to be essential for the 
development of EAM beyond the well established Th1, Th2 concept (106, 107). 
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In addition, also other disease models of autoimmunity are IL-17 depending such 
as EAE or collagen-induced arthritis (151-153).  
Type I IFNs also act directly on activated T-cells. In the absence of inflammation, 
antigen injection into animals causes antigen-specific T-cells to become activated 
and, rapidly thereafter, die (154, 155). Marrack and co-workers identified type I 
IFN as a survival signal for activated T-cells (156). These results support our 
observed phenotype of reduced in vitro T-cell expansion after immunization with 
fully competent and activated wt bmDCs.  
Taken together, type I IFN affects the induction of autoimmune myocarditis on 
many levels. Our research clearly demonstrates a role for type I IFN in disease 
induction. However, future investigations of type I IFN influencing pre-existing 
autoimmune responses will be of major interest to model IFN therapy of chronic 
myocarditis patients with autoimmune pathogenesis.  
 
In summary, we could demonstrate that TLR signalling affects the induction of 
heart specific autoimmunity on many levels. We believe that further research on 
TLR signalling induced autoimmunity and the identification of endogenous TLR 
ligands may contribute to novel treatment strategies against autoimmune induced 
heart failure and also other autoimmune diseases.  
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Abbreviations 
APC   Antigen-presenting cell 
BALB/c  Mouse strain (IAd haplotype) 
BmDCs  Bone marrow derived dendritic cells 
CAB   Chromotrope-Anilin Blue Staining 
CAM   Cell adhesion molecules 
CD   Cluster of differentiation 
CFA   Complete Freund`s adjuvant 
CpG   Cytidine–phosphate–guanosine repeats 
cpm   Counts per minute 
CVB3   Coxsackievirus B3 
DC   Dendritic cell 
DCM   Dilated Cardiomyopathy 
DD   Death-domain 
EAE   Experimental Autoimmune Encephalomyelitis  
EAM   Experimental Autoimmune Myocarditis 
EAU   Experimental Autoimmune Uveitis  
EDD   End-diastolic left-ventricular diameter  
ELISA   Enzyme-linked immunosorbent assay 
ESD   End-systolic left-ventricular diameter 
FACS   Fluorescence-activated cell-sorting 
FCS   Fetal calf serum 
FS   Fractional shortening  
HCMV  Human cytomegalovirus 
HE   Hemotoxylin & Eosin 
HSP   Heat-shock protein 
HSV1   Herpes Simplex Virus I 
HW/BW  Heart weight-body weight  
i.p.   Intraperitoneal 
i.v.   Intravenous 
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IFN   Interferon 
IFNαβRko  Interferon-alpha-beta receptor knockout mice 
Ig   Immunoglobulin 
IL   Interleukin 
IL-1R   Interleukin 1 receptor (IL-1R) 
IRAK   IL-1R-associated kinase 
IRF   Interferon-response factor 
IVS   Intra-ventricular septum 
KO   knock-out 
LPS   Lipopolysacharide 
LRR   Leucine rich repeats 
LTA   Lipo-teichoic acid 
MHC   Major histocompatibility complex  
MMTV  Mouse mammary tumor virus 
MyD88  Myeloid differentiation primary-response protein 88 
MyHC-alpha  Myosin Heavy-Chain-alpha derived peptide 
ND    Not determined 
NF-kB,   Nuclear factor-kB 
NO   Nitric oxide 
PAMPs  Pathogen-associated molecular patterns  
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PG   Peptidoglycan 
PI   Propidium iodide 
PKC   Protein Kinase C 
PMA   Phorbol myristate acetate 
PRRs   Pattern-recognition receptors 
PW   Left-ventricular posterior wall 
RSV    Respiratory syncytial virus 
SARM   Sterile alpha- and armadillo-motif-containing protein 
SCID   Severe combined immunodeficiency 
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SLE   Systemic Lupus Erythematosus 
TIR   Toll/IL-1R homology domain 
TIRAP  TIR-domain-containing adaptor protein 
TLR   Toll-like Receptor 
TNF- lpha  Tumour necrosis factor alpha 
TRAM   TRIF-related adaptor molecule 
TRIF TIR-domain-containing adaptor protein inducing interferon-
beta 
Vcf   Velocity of circumferential fibre shortening  
wt   Wild-type 
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